Functional	O
uncoupling	O
of	O
the	O
Janus	O
kinase	O
3-Stat5	O
pathway	O
in	O
malignant	O
growth	O
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1-transformed	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transforms	O
cytokine	B-protein
-dependent	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
causes	O
adult	O
T	O
cell	O
leukemia	O
.	O

Janus	B-protein
tyrosine	I-protein
kinase	I-protein
(	I-protein
Jak	I-protein
)	I-protein
3	I-protein
and	O
transcription	B-protein
factors	I-protein
Stat5a	B-protein
and	O
Stat5b	B-protein
are	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
are	O
constitutively	O
hyperactivated	O
in	O
both	O
HTLV-1-transformed	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
lymphocytes	B-cell_type
isolated	O
from	O
HTLV-1-infected	O
patients	O
;	O
therefore	O
,	O
a	O
critical	O
role	O
for	O
the	O
Jak3-Stat5	O
pathway	O
in	O
the	O
progression	O
of	O
this	O
disease	O
has	O
been	O
postulated	O
.	O

We	O
recently	O
reported	O
that	O
tyrphostin	O
AG-490	O
selectively	O
blocked	O
IL-2	O
activation	O
of	O
Jak3/Stat5	B-protein
and	O
growth	O
of	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Here	O
we	O
demonstrate	O
that	O
disruption	O
of	O
Jak3/Stat5a/b	O
signaling	O
with	O
AG-490	O
(	O
50	O
&	O
mgr	O
;	O
M	O
)	O
blocked	O
the	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
but	O
paradoxically	O
failed	O
to	O
inhibit	O
the	O
proliferation	O
of	O
HTLV-1-transformed	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HuT-102	B-cell_line
and	O
MT-2	B-cell_line
.	O

Structural	O
homologues	O
of	O
AG-490	O
also	O
inhibited	O
the	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
HTLV-1-infected	B-cell_type
cells	I-cell_type
.	O

Disruption	O
of	O
constitutive	O
Jak3/Stat5	O
activation	O
by	O
AG-490	O
was	O
demonstrated	O
by	O
inhibition	O
of	O
1	O
)	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
,	O
Stat5a	B-protein
(	O
Tyr	O
(	O
694	O
)	O
)	O
,	O
and	O
Stat5b	B-protein
(	O
Tyr	O
(	O
699	O
)	O
)	O
;	O
2	O
)	O
serine	O
phosphorylation	O
of	O
Stat5a	B-protein
(	O
Ser	O
(	O
726	O
)	O
)	O
as	O
determined	O
by	O
a	O
novel	O
phosphospecific	B-protein
Ab	I-protein
;	O
and	O
3	O
)	O
Stat5a/b	O
DNA	O
binding	O
to	O
the	O
Stat5-responsive	B-DNA
beta-casein	I-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
AG-490	O
had	O
no	O
effect	O
on	O
DNA	O
binding	O
by	O
p50/p65	B-protein
components	I-protein
of	O
NF-kappaB	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
the	O
HTLV-1-encoded	B-protein
phosphoprotein	I-protein
,	I-protein
Tax	I-protein
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
Jak3-Stat5	O
pathway	O
in	O
HTLV-1-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
has	O
become	O
functionally	O
redundant	O
for	O
proliferation	O
.	O

Reversal	O
of	O
this	O
functional	O
uncoupling	O
may	O
be	O
required	O
before	O
Jak3/Stat5	O
inhibitors	O
will	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
this	O
malignancy	O
.	O

'_9	NULL
Analytes	NULL
=	NULL
Comprehensive	NULL
Analysis	NULL
n	NULL
MICFOVUG	NULL
Wim	NULL
Ba	NULL
,	NULL
Bb	NULL
,	NULL
C3a	NULL
,	NULL
C4a	NULL
,	NULL
C4d	NULL
,	NULL
CSa	NULL
,	NULL
s	NULL
SCS5b-9	NULL
,	NULL
Factor	NULL
H	NULL
,	NULL
Factor	NULL
|	NULL
QUIpEL	NULL
MULTIPLEX	NULL
I	NULL
ill	NULL
``	NULL
``	NULL
A	NULL
SE	NULL
ANTS	NULL
ty	NULL
ay	NULL
#	NULL
m	NULL
meJournal	NULL
of	NULL
Functional	NULL
Uncoupling	NULL
of	NULL
the	NULL
Janus	NULL
Kinase	NULL
ﬁlm-	NULL
“	NULL
Immunolo	NULL
gy	NULL
3-Stat5	NULL
Pathway	NULL
in	NULL
Malignant	NULL
Growth	NULL
of	NULL
Human	NULL
T	NULL
Cell	NULL
Leukemia	NULL
Virus	NULL
Type	NULL
1-Transformed	NULL
Human	NULL
T	NULL
Cells	NULL
\ge	NULL
?	NULL

u	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Robert	NULL
A.	NULL
Kirken	NULL
,	NULL
Rebecca	NULL
A.	NULL
Erwin	NULL
,	NULL
Lihua	NULL
Wang	NULL
,	NULL
Yuling	NULL
Wang	NULL
,	NULL
Hallgeir	NULL
Rui	NULL
and	NULL
William	NULL
L.	NULL
Farrar	NULL
J	NULL
Immunol	NULL
2000	NULL
;	NULL
165:5097-5104	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.165.9.5097	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/165/9/5097	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
56	NULL
articles	NULL
,	NULL
37	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/165/9/5097	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Functional	NULL
Uncoupling	NULL
of	NULL
the	NULL
Janus	NULL
Kinase	NULL
3-Stat5	NULL
Pathway	NULL
in	NULL
Malignant	NULL
Growth	NULL
of	NULL
Human	NULL
T	NULL
Cell	NULL
Leukemia	NULL
Virus	NULL
Type	NULL
1-Transformed	NULL
Human	NULL
T	NULL
Cells	NULL
!	NULL

Robert	NULL
A.	NULL
Kirken	NULL
,	NULL
``	NULL
``	NULL
*	NULL
``	NULL
Rebecca	NULL
A.	NULL
Erwin	NULL
,	NULL
``	NULL
**	NULL
Lihua	NULL
Wang	NULL
,	NULL
*	NULL
Yuling	NULL
Wang	NULL
,	NULL
*	NULL
Hallgeir	NULL
Rui	NULL
,	NULL
``	NULL
and	NULL
William	NULL
L.	NULL
Farrar*	NULL
Human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
transforms	NULL
cytokine-dependent	NULL
T	NULL
lymphocytes	NULL
and	NULL
causes	NULL
adult	NULL
T	NULL
cell	NULL
leukemia	NULL
.	NULL

Janus	NULL
tyrosine	NULL
kinase	NULL
(	NULL
Jak	NULL
)	NULL
3	NULL
and	NULL
transcription	NULL
factors	NULL
StatSa	NULL
and	NULL
StatS5b	NULL
are	NULL
essential	NULL
for	NULL
the	NULL
proliferation	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
are	NULL
constitutively	NULL
hyperactivated	NULL
in	NULL
both	NULL
HTLV-1-transformed	NULL
human	NULL
T	NULL
cell	NULL
lines	NULL
and	NULL
lymphocytes	NULL
isolated	NULL
from	NULL
HTLV-1-infected	NULL
patients	NULL
;	NULL
therefore	NULL
,	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
the	NULL
Jak3-Stat5	NULL
pathway	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
this	NULL
disease	NULL
has	NULL
been	NULL
postulated	NULL
.	NULL

We	NULL
recently	NULL
reported	NULL
that	NULL
tyrphostin	NULL
AG-490	NULL
selectively	NULL
blocked	NULL
IL-2	NULL
activation	NULL
of	NULL
Jak3/Stat5	NULL
and	NULL
growth	NULL
of	NULL
murine	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
disruption	NULL
of	NULL
Jak3/StatS5a/b	NULL
signaling	NULL
with	NULL
AG-490	NULL
(	NULL
50	NULL
mM	NULL
)	NULL
blocked	NULL
the	NULL
proliferation	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
but	NULL
paradoxically	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
HTLV-1-transformed	NULL
human	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
.	NULL

Structural	NULL
homologues	NULL
of	NULL
AG-490	NULL
also	NULL
inhibited	NULL
the	NULL
proliferation	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
HTLV-1-infected	NULL
cells	NULL
.	NULL

Disruption	NULL
of	NULL
constitutive	NULL
Jak3/Stat5	NULL
activation	NULL
by	NULL
AG-490	NULL
was	NULL
demonstrated	NULL
by	NULL
inhibition	NULL
of	NULL
1	NULL
)	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
,	NULL
StatSa	NULL
and	NULL
StatSb	NULL
(	NULL
Tyr®	NULL
``	NULL
``	NULL
)	NULL
;	NULL
2	NULL
)	NULL
serine	NULL
phosphorylation	NULL
of	NULL
Stat5a	NULL
(	NULL
Ser'**	NULL
)	NULL
as	NULL
determined	NULL
by	NULL
a	NULL
novel	NULL
phosphospecific	NULL
Ab	NULL
;	NULL
and	NULL
3	NULL
)	NULL
StatSa/b	NULL
DNA	NULL
binding	NULL
to	NULL
the	NULL
Stat5-responsive	NULL
B-casein	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
AG-490	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
DNA	NULL
binding	NULL
by	NULL
p50/p65	NULL
components	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
activated	NULL
by	NULL
the	NULL
HTLV-1-encoded	NULL
phosphoprotein	NULL
,	NULL
Tax	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
Jak3-Stat5	NULL
pathway	NULL
in	NULL
HTLV-1-transformed	NULL
T	NULL
cells	NULL
has	NULL
become	NULL
functionally	NULL
redundant	NULL
for	NULL
proliferation	NULL
.	NULL

Reversal	NULL
of	NULL
this	NULL
functional	NULL
uncoupling	NULL
may	NULL
be	NULL
required	NULL
before	NULL
Jak3/Stat5	NULL
inhibitors	NULL
will	NULL
be	NULL
useful	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
this	NULL
malignancy	NULL
.	NULL

-	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2000	NULL
,	NULL
165	NULL
:	NULL
5097-5104.	NULL
uman	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-1	NULL
)	NULL
*	NULL
is	NULL
a	NULL
ret-	NULL
rovirus	NULL
that	NULL
serves	NULL
as	NULL
the	NULL
etiological	NULL
agent	NULL
for	NULL
adult	NULL
T	NULL
cell	NULL
leukemia	NULL
,	NULL
an	NULL
aggressive	NULL
and	NULL
frequently	NULL
fatal	NULL
malignancy	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
virus	NULL
dramatically	NULL
alters	NULL
T	NULL
lymphocyte	NULL
growth	NULL
patterns	NULL
(	NULL
4	NULL
)	NULL
,	NULL
while	NULL
infected	NULL
patients	NULL
generally	NULL
display	NULL
clonal	NULL
expansion	NULL
of	NULL
CD4	NULL
*	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
lymphocytes	NULL
(	NULL
7	NULL
)	NULL
.	NULL

HTLV-1-mediated	NULL
transformation	NULL
or	NULL
transition	NULL
from	NULL
a	NULL
cytokine-dependent	NULL
to	NULL
an	NULL
independent	NULL
phase	NULL
of	NULL
growth	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
Tax	NULL
,	NULL
a	NULL
40-kDa	NULL
regulatory	NULL
phosphoprotein	NULL
encoded	NULL
by	NULL
the	NULL
HTLV-1	NULL
virus	NULL
(	NULL
8-11	NULL
)	NULL
.	NULL

Tax	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
the	NULL
transcription	NULL
of	NULL
several	NULL
genes	NULL
involved	NULL
in	NULL
promoting	NULL
cell	NULL
growth	NULL
by	NULL
enhancing	NULL
degradation	NULL
of	NULL
IxB-a	NULL
and	NULL
IxB-f3	NULL
,	NULL
thereby	NULL
*Department	NULL
of	NULL
Integrative	NULL
Biology	NULL
and	NULL
Pharmacology	NULL
,	NULL
University	NULL
of	NULL
Texas	NULL
Health	NULL
Science	NULL
Center	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
;	NULL
*IRSP	NULL
,	NULL
Science	NULL
Applications	NULL
International	NULL
Corporation	NULL
Frederick	NULL
,	NULL
and	NULL
*Division	NULL
of	NULL
Basic	NULL
Sciences	NULL
,	NULL
Cytokine	NULL
Molecular	NULL
Mechanisms	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Immunoregulation	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21702	NULL
;	NULL
and	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Uniformed	NULL
Services	NULL
University	NULL
of	NULL
the	NULL
Health	NULL
Sciences	NULL
,	NULL
Be-thesda	NULL
,	NULL
MD	NULL
20814	NULL
Received	NULL
for	NULL
publication	NULL
September	NULL
7	NULL
,	NULL
1999	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
August	NULL
2	NULL
,	NULL
2000	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Roche	NULL
Foundation	NULL
(	NULL
Grant	NULL
862506002	NULL
)	NULL
and	NULL
the	NULL
American	NULL
Lung	NULL
Association	NULL
(	NULL
CI-008-N	NULL
,	NULL
to	NULL
R.A.K	NULL
.	NULL
)	NULL

.	NULL

2	NULL
RA.K	NULL
.	NULL

and	NULL
R.A.E	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
the	NULL
studies	NULL
.	NULL

*	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Robert	NULL
A.	NULL
Kirken	NULL
,	NULL
Department	NULL
of	NULL
Integrative	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
Texas	NULL
Health	NULL
Science	NULL
Center	NULL
,	NULL
Medical	NULL
Science	NULL
Building	NULL
,	NULL
Room	NULL
4.218	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
rkirken	NULL
@	NULL
farmr1	NULL
.	NULL

med.uth.tmc.edu	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
HTLV-1	NULL
,	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus-1	NULL
;	NULL
Jak	NULL
,	NULL
Janus	NULL
tyrosine	NULL
kinase	NULL
;	NULL
y	NULL
,	NULL
,	NULL
common	NULL
IL-2R	NULL
chain	NULL
;	NULL
rau	NULL
,	NULL
relative	NULL
absorbance	NULL
units	NULL
.	NULL

Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
activating	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
members	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
,	NULL
which	NULL
subsequently	NULL
promote	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
its	NULL
receptor	NULL
(	NULL
14	NULL
)	NULL
,	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proto-oncogenes	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
Stat5	NULL
(	NULL
16	NULL
)	NULL
as	NULL
well	NULL
as	NULL
associate	NULL
with	NULL
mitogen-activated	NULL
protein/extracellular	NULL
signal-related	NULL
kinase	NULL
kinase	NULL
(	NULL
17	NULL
)	NULL
and	NULL
Ras	NULL
(	NULL
Ref	NULL
.	NULL

9	NULL
;	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Ref	NULL
.	NULL

18	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
HTLV-1	NULL
may	NULL
also	NULL
promote	NULL
constitutive	NULL
activation	NULL
of	NULL
a	NULL
family	NULL
of	NULL
cytokine-activated	NULL
signaling	NULL
proteins	NULL
known	NULL
as	NULL
Janus	NULL
tyrosine	NULL
kinases	NULL
(	NULL
Jaks	NULL
)	NULL
and	NULL
Stat	NULL
transcription	NULL
factors	NULL
.	NULL

Under	NULL
normal	NULL
conditions	NULL
,	NULL
polypeptide	NULL
hormones	NULL
and	NULL
cytokines	NULL
induce	NULL
transient	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
these	NULL
latent	NULL
signaling	NULL
molecules	NULL
.	NULL

Current	NULL
models	NULL
hold	NULL
that	NULL
oligomerization	NULL
of	NULL
the	NULL
receptor	NULL
complex	NULL
by	NULL
growth	NULL
factors	NULL
results	NULL
in	NULL
autophosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Jaks	NULL
,	NULL
which	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
phosphorylate	NULL
tyrosine	NULL
residues	NULL
located	NULL
within	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
these	NULL
receptors	NULL
so	NULL
that	NULL
Stats	NULL
are	NULL
transiently	NULL
recruited	NULL
via	NULL
their	NULL
Sre	NULL
homology	NULL
2	NULL
domains	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
Jak	NULL
enzymes	NULL
catalyze	NULL
Stat	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
facilitating	NULL
their	NULL
dimerization	NULL
and	NULL
disengagement	NULL
from	NULL
the	NULL
receptor	NULL
complex	NULL
upon	NULL
which	NULL
they	NULL
migrate	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
bind	NULL
select	NULL
promoter	NULL
elements	NULL
,	NULL
and	NULL
ultimately	NULL
regulate	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Serine	NULL
kinases	NULL
also	NULL
regulate	NULL
Stat	NULL
protein	NULL
activity	NULL
.	NULL

Specifically	NULL
,	NULL
serine	NULL
residue	NULL
$	NULL
727	NULL
of	NULL
Statla	NULL
and	NULL
Stat3	NULL
constitutes	NULL
a	NULL
major	NULL
phosphorylation	NULL
site	NULL
and	NULL
is	NULL
important	NULL
for	NULL
IFN-induced	NULL
nuclear	NULL
translocation	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
maximal	NULL
transcriptional	NULL
activation	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

We	NULL
recently	NULL
reported	NULL
that	NULL
Stata	NULL
and	NULL
Stat5b	NULL
become	NULL
phosphorylated	NULL
on	NULL
serine	NULL
residues	NULL
following	NULL
activation	NULL
of	NULL
lymphocytes	NULL
by	NULL
prolactin	NULL
or	NULL
IL-2	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

We	NULL
subsequently	NULL
mapped	NULL
these	NULL
sites	NULL
to	NULL
$	NULL
726	NULL
in	NULL
StatSa	NULL
and	NULL
S731	NULL
in	NULL
Stat5b	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
Stat5a/b	NULL
are	NULL
activated	NULL
by	NULL
the	NULL
lym-phocyte-restricted	NULL
enzyme	NULL
,	NULL
Jak3	NULL
.	NULL

Jak3	NULL
is	NULL
exclusively	NULL
activated	NULL
by	NULL
the	NULL
cytokines	NULL
that	NULL
use	NULL
the	NULL
common	NULL
IL-2R	NULL
chain	NULL
(	NULL
y	NULL
,	NULL
)	NULL
and	NULL
include	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-9	NULL
,	NULL
IL-13	NULL
,	NULL
and	NULL
IL-15	NULL
(	NULL
19	NULL
,	NULL
26-29	NULL
)	NULL
.	NULL

Mutations	NULL
or	NULL
0022-1767/00/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5098	NULL
HTLV-1	NULL
TRANSFORMATION	NULL
DOES	NULL
NOT	NULL
REQUIRE	NULL
JAK3/STATS5	NULL
PATHWAY	NULL
deletions	NULL
that	NULL
disrupt	NULL
Jak3	NULL
activation	NULL
and/or	NULL
its	NULL
association	NULL
with	NULL
the	NULL
y	NULL
-chain	NULL
are	NULL
manifested	NULL
as	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
syndrome	NULL
in	NULL
humans	NULL
and	NULL
mice	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
activation	NULL
of	NULL
StatSa	NULL
and	NULL
Stat5b	NULL
has	NULL
been	NULL
determined	NULL
to	NULL
be	NULL
unconditionally	NULL
required	NULL
for	NULL
IL-2-mediated	NULL
T	NULL
cell	NULL
proliferation	NULL
based	NULL
upon	NULL
gene	NULL
deletion	NULL
experiments	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Whereas	NULL
Jak	NULL
and	NULL
Stat	NULL
proteins	NULL
are	NULL
normally	NULL
unphosphorylated	NULL
and	NULL
inactive	NULL
in	NULL
quiescent	NULL
lymphocytes	NULL
,	NULL
HTLV-1-transformed	NULL
cells	NULL
,	NULL
including	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
,	NULL
typically	NULL
show	NULL
constitutive	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stats	NULL
(	NULL
31-33	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
lymphocytes	NULL
obtained	NULL
from	NULL
HTLV-1-infected	NULL
patients	NULL
display	NULL
hypertyr-osine-phosphorylated	NULL
Jak3	NULL
,	NULL
Stat5	NULL
,	NULL
and	NULL
Stat3	NULL
,	NULL
but	NULL
not	NULL
Jak2	NULL
,	NULL
Jak1	NULL
,	NULL
or	NULL
Tyk-2	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Constitutively	NULL
active	NULL
Jak	NULL
and	NULL
Stat	NULL
proteins	NULL
are	NULL
also	NULL
commonly	NULL
observed	NULL
in	NULL
a	NULL
number	NULL
of	NULL
other	NULL
malignancies	NULL
,	NULL
including	NULL
Src-	NULL
,	NULL
v-Abl-	NULL
,	NULL
and	NULL
EBV-transformed	NULL
cell	NULL
lines	NULL
and	NULL
patient	NULL
lymphocytes	NULL
(	NULL
35-41	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
causal	NULL
relationship	NULL
between	NULL
malignant	NULL
growth	NULL
has	NULL
not	NULL
been	NULL
established	NULL
,	NULL
nor	NULL
is	NULL
it	NULL
clear	NULL
whether	NULL
disruption	NULL
of	NULL
this	NULL
Jak/Stat	NULL
signaling	NULL
pathway	NULL
will	NULL
reverse	NULL
the	NULL
phenotypic	NULL
condition	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
reported	NULL
that	NULL
tyrphostin	NULL
AG-490	NULL
,	NULL
a	NULL
derivative	NULL
of	NULL
benzylidine	NULL
malononitrile	NULL
that	NULL
resembles	NULL
erbstatin	NULL
moieties	NULL
,	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
the	NULL
Jak3/Stat5	NULL
signaling	NULL
pathway	NULL
in	NULL
human	NULL
and	NULL
murine	NULL
T	NULL
cells	NULL
(	NULL
42-45	NULL
)	NULL
.	NULL

While	NULL
this	NULL
drug	NULL
also	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
effects	NULL
on	NULL
Jak2	NULL
,	NULL
it	NULL
fails	NULL
to	NULL
inhibit	NULL
Jak1	NULL
,	NULL
Tyk2	NULL
,	NULL
or	NULL
a	NULL
series	NULL
of	NULL
tyrosine	NULL
kinases	NULL
expressed	NULL
in	NULL
lymphocytes	NULL
,	NULL
including	NULL
Lck	NULL
,	NULL
Lyn	NULL
,	NULL
Bik	NULL
,	NULL
Syk	NULL
,	NULL
Src	NULL
,	NULL
and	NULL
Zap70	NULL
(	NULL
43	NULL
,	NULL
46	NULL
)	NULL
.	NULL

The	NULL
studies	NULL
described	NULL
in	NULL
this	NULL
report	NULL
were	NULL
aimed	NULL
at	NULL
investigating	NULL
whether	NULL
AG-490	NULL
could	NULL
preferentially	NULL
inhibit	NULL
constitutive	NULL
and	NULL
cytokine-induced	NULL
activation	NULL
of	NULL
the	NULL
Jak3/Stat5	NULL
signaling	NULL
cascade	NULL
within	NULL
HTLV-1-transformed	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
subsequently	NULL
disrupt	NULL
malignant	NULL
cell	NULL
growth	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
culture	NULL
and	NULL
treatment	NULL
Freshly	NULL
explanted	NULL
human	NULL
T	NULL
lymphocytes	NULL
were	NULL
obtained	NULL
from	NULL
normal	NULL
do-mors	NULL
,	NULL
purified	NULL
by	NULL
isocentrifugation	NULL
,	NULL
and	NULL
activated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
1	NULL
pg/ml	NULL
PHA	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
catalogue	NULL
no	NULL
.	NULL

F2442	NULL
,	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
penicillin-streptomycin	NULL
(	NULL
50	NULL
IU/ml	NULL
and	NULL
50	NULL
pg/ml	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

MT-2	NULL
and	NULL
HuT-102	NULL
HTLV-1-infected	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
the	NULL
above	NULL
medium	NULL
without	NULL
PHA	NULL
.	NULL

T	NULL
lymphocytes	NULL
were	NULL
made	NULL
quiescent	NULL
by	NULL
washing	NULL
and	NULL
incubating	NULL
for	NULL
24	NULL
h	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
1	NULL
%	NULL
FCS	NULL
before	NULL
exposure	NULL
to	NULL
cytokines	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
varying	NULL
concentrations	NULL
of	NULL
AG-490	NULL
(	NULL
catalogue	NULL
no	NULL
.	NULL

658401	NULL
,	NULL
Cal-biochem	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
16	NULL
h	NULL
as	NULL
described	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
100	NULL
nM	NULL
human	NULL
rIL-2	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
TNF-a	NULL
,	NULL
or	NULL
IL-15	NULL
(	NULL
PeproTech	NULL
,	NULL
Rock	NULL
Hill	NULL
,	NULL
NJ	NULL
)	NULL
at	NULL
37°C	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
corresponding	NULL
figure	NULL
legends	NULL
.	NULL

Cell	NULL
pellets	NULL
were	NULL
frozen	NULL
at	NULL
-70°C	NULL
.	NULL

Proliferation	NULL
assays	NULL
Quiescent	NULL
T	NULL
,	NULL
MT-2	NULL
,	NULL
and	NULL
HuT-102	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10*/well	NULL
)	NULL
were	NULL
plated	NULL
in	NULL
flat-bottom	NULL
96-well	NULL
microtiter	NULL
plates	NULL
in	NULL
200	NULL
ul	NULL
of	NULL
growth	NULL
medium	NULL
(	NULL
de-scribed	NULL
above	NULL
)	NULL
with	NULL
1	NULL
%	NULL
FCS	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
for	NULL
16	NULL
h	NULL
with	NULL
AG-490	NULL
or	NULL
tyrphostin	NULL
A25	NULL
,	NULL
B44	NULL
,	NULL
B46	NULL
,	NULL
B48	NULL
,	NULL
or	NULL
B50	NULL
(	NULL
Calbiochem	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
as	NULL
described	NULL
above	NULL
,	NULL
pulsed	NULL
for	NULL
the	NULL
remaining	NULL
4	NULL
h	NULL
of	NULL
the	NULL
assay	NULL
with	NULL
[	NULL
°H	NULL
[	NULL
Jthy-midine	NULL
(	NULL
0.5	NULL
wCi/200	NULL
pl	NULL
)	NULL
,	NULL
and	NULL
harvested	NULL
onto	NULL
glass-fiber	NULL
filters	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
was	NULL
analyzed	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Solubilization	NULL
of	NULL
membrane	NULL
proteins	NULL
and	NULL
immunoprecipitation	NULL
Frozen	NULL
cell	NULL
pellets	NULL
were	NULL
thawed	NULL
on	NULL
ice	NULL
and	NULL
solubilized	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
10°	NULL
cells/ml	NULL
!	NULL
)	NULL

containing	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
30	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
,	NULL
50	NULL
mM	NULL
sodium	NULL
fluoride	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
ortho-vanadate	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
5	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
ug/ml	NULL
pepstatin	NULL
A	NULL
,	NULL
and	NULL
2	NULL
pg/ml	NULL
leupeptin	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
rotated	NULL
end-over-end	NULL
at	NULL
4°C	NULL
for	NULL
60	NULL
min	NULL
,	NULL
and	NULL
insoluble	NULL
material	NULL
was	NULL
pelleted	NULL
at	NULL
12,000	NULL
X	NULL
g	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
experiment	NULL
,	NULL
supernatants	NULL
were	NULL
incubated	NULL
with	NULL
5	NULL
pg/ml	NULL
polyclonal	NULL
rabbit	NULL
antisera	NULL
raised	NULL
against	NULL
carboxyl1-	NULL
terminal	NULL
peptides	NULL
corresponding	NULL
to	NULL
StatSa	NULL
(	NULL
LDARLSPPAGLFTSARSSLS	NULL
)	NULL
or	NULL
StatSb	NULL
MDSQWIPHAQS	NULL
)	NULL
.	NULL

Site-specific	NULL
anti-Stat5	NULL
phosphoserine	NULL
Abs	NULL
were	NULL
similarly	NULL
produced	NULL
to	NULL
the	NULL
corresponding	NULL
phosphopeptide	NULL
sequence	NULL
DQAP	NULL
[	NULL
pSJPAVC	NULL
,	NULL
and	NULL
all	NULL
peptides	NULL
were	NULL
conjugated	NULL
to	NULL
keyhole	NULL
limpet	NULL
he-mocyanin	NULL
and	NULL
used	NULL
as	NULL
immunogens	NULL
in	NULL
rabbits	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Rabbit	NULL
anti-Jak3	NULL
was	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
28	NULL
)	NULL
,	NULL
and	NULL
anti-phosphotyrosine	NULL
or	NULL
antiphosphotyrosine	NULL
StatSa/b	NULL
(	NULL
¥694/699	NULL
)	NULL
mAbs	NULL
were	NULL
obtained	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
;	NULL
catalogue	NULL
no	NULL
.	NULL

05-321	NULL
and	NULL
05-495	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Abs	NULL
were	NULL
captured	NULL
by	NULL
incubation	NULL
for	NULL
45	NULL
min	NULL
with	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Precipitated	NULL
material	NULL
was	NULL
eluted	NULL
by	NULL
boiling	NULL
in	NULL
SDS-sample	NULL
buffer	NULL
for	NULL
4	NULL
min	NULL
and	NULL
was	NULL
subjected	NULL
to	NULL
7.5	NULL
%	NULL
SDS-PAGE	NULL
under	NULL
reducing	NULL
conditions	NULL
.	NULL

All	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
(	NULL
catalogue	NULL
no	NULL
.	NULL

1PVHO0010	NULL
,	NULL
Immo-bilon	NULL
,	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

All	NULL
Western	NULL
blots	NULL
used	NULL
the	NULL
above	NULL
described	NULL
Abs	NULL
diluted	NULL
1/1000	NULL
in	NULL
blocking	NULL
buffer	NULL
for	NULL
1	NULL
h	NULL
,	NULL
while	NULL
phosphoserine	NULL
Stat5	NULL
Abs	NULL
were	NULL
blotted	NULL
at	NULL
1/5000	NULL
for	NULL
20	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

EMSA	NULL
AG-490-treated	NULL
and	NULL
control	NULL
(	NULL
DMSO-treated	NULL
)	NULL
cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
(	NULL
20,000	NULL
X	NULL
g	NULL
for	NULL
1	NULL
min	NULL
at	NULL
4°C	NULL
)	NULL
and	NULL
subsequently	NULL
washed	NULL
in	NULL
5	NULL
vol	NULL
of	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
100	NULL
mM	NULL
PMSF	NULL
,	NULL
5	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
ug/ml	NULL
pepstatin	NULL
A	NULL
,	NULL
and	NULL
2	NULL
pg/ml	NULL
leupeptin	NULL
;	NULL
centrifuged	NULL
;	NULL
then	NULL
lysed	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
supplemented	NULL
with	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
and	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
nuclei-containing	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
equal	NULL
volumes	NULL
of	NULL
low	NULL
salt	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
20	NULL
mM	NULL
KCI	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
protease	NULL
inhibitors	NULL
)	NULL
and	NULL
high	NULL
salt	NULL
buffer	NULL
(	NULL
low	NULL
salt	NULL
buffer	NULL
containing	NULL
800	NULL
mM	NULL
KC	NULL
]	NULL
.	NULL

This	NULL
fraction	NULL
was	NULL
then	NULL
isolated	NULL
by	NULL
centrifugation	NULL
at	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
and	NULL
supernatants	NULL
were	NULL
saved	NULL
as	NULL
nuclear	NULL
protein	NULL
extract	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
to	NULL
detect	NULL
Stat5a/b	NULL
DNA	NULL
binding	NULL
activity	NULL
using	NULL
a	NULL
Stats	NULL
DNA	NULL
binding	NULL
sequence	NULL
corresponding	NULL
to	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
B-casein	NULL
gene	NULL
(	NULL
5'-AGATTITCTAGGAATTCAATCC-3	NULL
'	NULL
)	NULL
or	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
element	NULL
Both	NULL
probes	NULL
were	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
°°P	NULL
]	NULL
dATP	NULL
.	NULL

Labeled	NULL
oligonucleotides	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
5	NULL
pug	NULL
of	NULL
nuclear-extracted	NULL
proteins	NULL
in	NULL
15	NULL
pl	NULL
of	NULL
binding	NULL
cocktail	NULL
(	NULL
50	NULL
mM	NULL
Tris-CI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
25	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
50	NULL
%	NULL
glycerol	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
2	NULL
h.	NULL
For	NULL
supershift	NULL
assays	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
with	NULL
1	NULL
pg	NULL
of	NULL
either	NULL
normal	NULL
rabbit	NULL
serum	NULL
or	NULL
antiserum	NULL
specific	NULL
to	NULL
Stat5a	NULL
,	NULL
Stat5b	NULL
,	NULL
or	NULL
p50/p65	NULL
NF-KB	NULL
(	NULL
catalogue	NULL
no	NULL
.	NULL

sc-1190X	NULL
and	NULL
sc-372X	NULL
,	NULL
respectively	NULL
,	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
,	NULL
then	NULL
incubated	NULL
with	NULL
**P-labeled	NULL
DNA	NULL
oligonucleotide	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
containing	NULL
0.25	NULL
%	NULL
TBE	NULL
,	NULL
which	NULL
were	NULL
prerun	NULL
in	NULL
0.25	NULL
%	NULL
TBE	NULL
buffer	NULL
for	NULL
1	NULL
h	NULL
at	NULL
100	NULL
V.	NULL
Samples	NULL
were	NULL
loaded	NULL
,	NULL
and	NULL
gels	NULL
were	NULL
run	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
approximately	NULL
2	NULL
h	NULL
at	NULL
150	NULL
V	NULL
,	NULL
then	NULL
dried	NULL
by	NULL
heating	NULL
under	NULL
vacuum	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
(	NULL
X-OMAT	NULL
,	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
at	NULL
-70°C	NULL
.	NULL

Results	NULL
AG-490	NULL
blocks	NULL
constitutive	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat5a/b	NULL
isolated	NULL
from	NULL
HTLV-1-transformed	NULL
human	NULL
T	NULL
cells	NULL
Previously	NULL
we	NULL
had	NULL
established	NULL
that	NULL
75	NULL
wM	NULL
of	NULL
the	NULL
Jak3	NULL
inhibitor	NULL
AG-490	NULL
potently	NULL
inhibited	NULL
IL-2-induced	NULL
cell	NULL
growth	NULL
of	NULL
the	NULL
murine	NULL
T	NULL
cell	NULL
clone	NULL
,	NULL
D10	NULL
(	NULL
42	NULL
)	NULL
.	NULL

We	NULL
next	NULL
wanted	NULL
to	NULL
assess	NULL
whether	NULL
AG-490	NULL
also	NULL
could	NULL
block	NULL
activation	NULL
of	NULL
Jak3/StatSa/b	NULL
in	NULL
HTLV-1-transformed	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
cells	NULL
that	NULL
display	NULL
constitutively	NULL
tyrosine-phosphorylated	NULL
forms	NULL
of	NULL
both	NULL
proteins	NULL
.	NULL

For	NULL
this	NULL
analysis	NULL
actively	NULL
growing	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
cells	NULL
were	NULL
equally	NULL
distributed	NULL
and	NULL
cultured	NULL
with	NULL
the	NULL
drug	NULL
for	NULL
16	NULL
h	NULL
,	NULL
then	NULL
stimulated	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Jak3	NULL
and	NULL
Stat5a/b	NULL
were	NULL
immunoprecipitated	NULL
from	NULL
cell	NULL
lysates	NULL
and	NULL
subsequently	NULL
blotted	NULL
with	NULL
anti-phosphotyrosine	NULL
Abs	NULL
(	NULL
4G10	NULL
)	NULL
or	NULL
anti-phosphotyrosine	NULL
Stat5	NULL
(	NULL
Y¥694/699	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Whereas	NULL
each	NULL
of	NULL
the	NULL
three	NULL
signaling	NULL
molecules	NULL
displayed	NULL
constitutive	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
MT-2	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
and	NULL
HuT-102	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
cells	NULL
(	NULL
Janes	NULL
a	NULL
,	NULL
e	NULL
,	NULL
and	NULL
i	NULL
)	NULL
,	NULL
AG-490	NULL
potently	NULL
inhibited	NULL
basal	NULL
and	NULL
noncytokine-inducible	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
(	NULL
Zanes	NULL
c	NULL
and	NULL
d	NULL
)	NULL
and	NULL
constitutive	NULL
and	NULL
IL-2-mediated	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
StatSa/b	NULL
(	NULL
lanes	NULL
g	NULL
,	NULL
A	NULL
,	NULL
k	NULL
,	NULL
and	NULL
F	NULL
)	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
.	NULL

Densitometric	NULL
analysis	NULL
and	NULL
normalization	NULL
of	NULL
constitutively	NULL
tyrosine-phosphorylated	NULL
Jak3	NULL
compared	NULL
with	NULL
total	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A.	NULL
MT-2	NULL
a	NULL
b	NULL
-c	NULL
d	NULL
WB	NULL
:	NULL
gement	NULL
o	NULL
PY	NULL
H.	NULL
gos	NULL
a	NULL
Jaks	NULL
-*	NULL
,	NULL
was	NULL
uas	NULL
yas	NULL
:	NULL
lel	NULL
5099	NULL
B.	NULL
HuT-102	NULL
fnwe	NULL
my	NULL
:	NULL
>	NULL
am	NULL
a	NULL
PY	NULL
U	NULL
cmmitlip	NULL
Ommus	NULL
tows	NULL
C	NULL
Jak3	NULL
6	NULL
biwalp	NULL
bas	NULL
4	NULL
IL2	NULL
0	NULL
=	NULL
0	NULL
&	NULL
)	NULL
;	NULL
.-	NULL
+	NULL
Treatment	NULL
:	NULL
|	NULL
pMso	NULL
AG490	NULL
|	NULL
Treatment	NULL
:	NULL
|ml	NULL
Imll	NULL
IP	NULL
:	NULL
o	NULL
Jaks	NULL
IP	NULL
:	NULL
a	NULL
Jaks	NULL
f	NULL
)	NULL
|	NULL
I	NULL
e	NULL
f	NULL
g	NULL
h	NULL
i	NULL
]	NULL
ko	NULL
d	NULL
wB	NULL
:	NULL
e	NULL
g	NULL
i	NULL
s	NULL
wB	NULL
:	NULL
Comap	NULL
mumps	NULL
swam	NULL
c.	NULL
PY	NULL
StatS	NULL
-	NULL
(	NULL
oen	NULL
eae	NULL
exeunt	NULL
a.	NULL
PY	NULL
Stats	NULL
7	NULL
a	NULL
PS	NULL
Stat5	NULL
ump	NULL
queee	NULL
cong	NULL
mast	NULL
ooy	NULL
g	NULL
a	NULL
PS	NULL
Stats	NULL
”	NULL
Pi—w	NULL
B	NULL
¥	NULL
4	NULL
Hm	NULL
“	NULL
a	NULL
Stats	NULL
%	NULL
%	NULL
bow	NULL
o	NULL
otpow	NULL
o	NULL
othowm	NULL
oF	NULL
o*	NULL
IL2	NULL
Treatment	NULL
:	NULL
|	NULL
DMSO	NULL
AG490	NULL
I|	NULL
DMSO	NULL
AG490	NULL
|	NULL
IP	NULL
:	NULL
o	NULL
StatSa	NULL
o.	NULL
StatSb	NULL
W	NULL
f=	NULL
4	NULL
i	NULL
4	NULL
fold	NULL
P	NULL
P	NULL
Wmuﬁﬁ-n—	NULL
a	NULL
Stato	NULL
IL2n	NULL
o	NULL
t	NULL
)	NULL
.n	NULL
t	NULL
.n	NULL
h	NULL
so	NULL
Treatment	NULL
:	NULL
I	NULL
DMSO	NULL
AG490	NULL
||	NULL
DMSO	NULL
AG490I	NULL
IP	NULL
:	NULL
a	NULL
StatSa	NULL
o	NULL
StatSb	NULL
FIGURE	NULL
1	NULL
.	NULL

AG-490	NULL
inhibits	NULL
constitutive	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
tyrosine/serine	NULL
phosphorylation	NULL
of	NULL
Stat5a/b	NULL
in	NULL
HTLV-1-transformed	NULL
T	NULL
cells	NULL
.	NULL

MT-2	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
or	NULL
Hut-102	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
DMSO	NULL
(	NULL
control	NULL
)	NULL
or	NULL
75	NULL
M	NULL
AG-490	NULL
for	NULL
16	NULL
h	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
10	NULL
min	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
100	NULL
nM	NULL
IL-2	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
then	NULL
immunoprecipitated	NULL
with	NULL
anti-Jak3	NULL
(	NULL
Zanes	NULL
a-d	NULL
)	NULL
,	NULL
blotted	NULL
with	NULL
antiphosphotyrosine	NULL
,	NULL
stripped	NULL
,	NULL
and	NULL
reprobed	NULL
with	NULL
polyclonal	NULL
Jak3	NULL
Abs	NULL
.	NULL

Alternatively	NULL
,	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
StatSa	NULL
(	NULL
Janes	NULL
e-A	NULL
)	NULL
or	NULL
Stat5b	NULL
(	NULL
lanes	NULL
i-1	NULL
)	NULL
,	NULL
blotted	NULL
with	NULL
monoclonal	NULL
antiphosphotyrosine	NULL
Stat5	NULL
,	NULL
polyclonal	NULL
phosphoserine	NULL
Stat5	NULL
(	NULL
$	NULL
726-StatSa	NULL
or	NULL
$	NULL
731	NULL
Stat5b	NULL
)	NULL
,	NULL
and	NULL
reblotted	NULL
with	NULL
monoclonal	NULL
pan	NULL
Stat5	NULL
.	NULL

Densi-tometry	NULL
and	NULL
normalization	NULL
of	NULL
Jak3	NULL
samples	NULL
isolated	NULL
from	NULL
DMSO-treated	NULL
compared	NULL
with	NULL
AG-490-treated	NULL
cells	NULL
showed	NULL
decreased	NULL
constitutive	NULL
(	NULL
without	NULL
IL-2	NULL
)	NULL
tyrosine	NULL
phosphorylation	NULL
for	NULL
MT-2	NULL
of	NULL
64	NULL
%	NULL
(	NULL
A	NULL
,	NULL
lane	NULL
a	NULL
,	NULL
of	NULL
0.671	NULL
relative	NULL
absorbance	NULL
units	NULL
(	NULL
rau	NULL
)	NULL
,	NULL
Zane	NULL
b	NULL
of	NULL
0.803	NULL
rau	NULL
,	NULL
lane	NULL
c	NULL
of	NULL
0.239	NULL
rau	NULL
,	NULL
and	NULL
lane	NULL
d	NULL
of	NULL
0.460	NULL
rau	NULL
)	NULL
and	NULL
for	NULL
Hut-102	NULL
of	NULL
71	NULL
%	NULL
(	NULL
B	NULL
,	NULL
lane	NULL
a	NULL
of	NULL
0.825	NULL
rau	NULL
,	NULL
lane	NULL
b	NULL
of	NULL
0.608	NULL
rau	NULL
,	NULL
lane	NULL
c	NULL
of	NULL
0.240	NULL
rau	NULL
,	NULL
and	NULL
lane	NULL
d	NULL
of	NULL
0.265	NULL
rau	NULL
)	NULL
.	NULL

protein	NULL
were	NULL
inhibited	NULL
by	NULL
64	NULL
and	NULL
71	NULL
%	NULL
for	NULL
MT-2	NULL
and	NULL
HuT-102	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
while	NULL
Stat5a/b	NULL
showed	NULL
a	NULL
corresponding	NULL
loss	NULL
of	NULL
phosphorylation	NULL
signal	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

HTLV-1	NULL
transformed	NULL
T	NULL
cells	NULL
display	NULL
constitutive	NULL
serine-phosphorylated	NULL
StatSa	NULL
(	NULL
S726	NULL
)	NULL
and	NULL
Stat5Sb	NULL
(	NULL
S731	NULL
)	NULL
that	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
AG-490	NULL
Statl	NULL
a	NULL
and	NULL
Stat3	NULL
are	NULL
serine	NULL
phosphorylated	NULL
at	NULL
residue	NULL
$	NULL
727	NULL
,	NULL
which	NULL
is	NULL
important	NULL
for	NULL
IFN-induced	NULL
nuclear	NULL
translocation	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
maximal	NULL
transcriptional	NULL
activation	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

This	NULL
site	NULL
is	NULL
located	NULL
within	NULL
a	NULL
consensus	NULL
PXSP	NULL
phosphoacceptor	NULL
site	NULL
for	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Recent	NULL
work	NULL
by	NULL
Zhang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
49	NULL
)	NULL
reported	NULL
that	NULL
phosphorylated	NULL
$	NULL
727	NULL
was	NULL
also	NULL
required	NULL
for	NULL
interaction	NULL
with	NULL
minichromosomal	NULL
maintenance	NULL
protein	NULL
5	NULL
and	NULL
was	NULL
necessary	NULL
for	NULL
maximum	NULL
transcriptional	NULL
activity	NULL
and	NULL
possibly	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Interestingly	NULL
,	NULL
IL-2	NULL
also	NULL
inducibly	NULL
regulates	NULL
serine	NULL
phosphorylation	NULL
of	NULL
StatSa	NULL
and	NULL
Stat5b	NULL
,	NULL
and	NULL
we	NULL
have	NULL
mapped	NULL
this	NULL
site	NULL
to	NULL
a	NULL
serine	NULL
residue	NULL
of	NULL
a	NULL
PSP	NULL
motif	NULL
found	NULL
in	NULL
StatSa	NULL
and	NULL
StatSb	NULL
(	NULL
23	NULL
,	NULL
25	NULL
)	NULL
.	NULL

To	NULL
specifically	NULL
analyze	NULL
the	NULL
phosphorylation	NULL
status	NULL
of	NULL
this	NULL
motif	NULL
in	NULL
StatSa	NULL
(	NULL
8726	NULL
)	NULL
and	NULL
StatS5b	NULL
(	NULL
S731	NULL
)	NULL
in	NULL
HTLV-1-transformed	NULL
cells	NULL
,	NULL
blots	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
were	NULL
next	NULL
probed	NULL
with	NULL
site-specific	NULL
phosphoserine	NULL
Abs	NULL
directed	NULL
to	NULL
phosphorylated	NULL
peptide	NULL
corresponding	NULL
to	NULL
aa	NULL
residues	NULL
721-729	NULL
of	NULL
human	NULL
StatSa	NULL
or	NULL
726-734	NULL
of	NULL
human	NULL
StatSb	NULL
.	NULL

Stat5a/b	NULL
isolated	NULL
from	NULL
quiescent	NULL
PHA-activated	NULL
human	NULL
T	NULL
cells	NULL
display	NULL
serine	NULL
phosphorylation	NULL
of	NULL
this	NULL
site	NULL
only	NULL
upon	NULL
IL-2	NULL
stimulation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
cells	NULL
primarily	NULL
displayed	NULL
constitutively	NULL
serine	NULL
phosphorylation	NULL
of	NULL
StatSa	NULL
(	NULL
lanes	NULL
e	NULL
and	NULL
f	NULL
)	NULL
,	NULL
but	NULL
not	NULL
Stat5b	NULL
(	NULL
lanes	NULL
i	NULL
and	NULL
j	NULL
)	NULL
.	NULL

AG-490	NULL
treatment	NULL
significantly	NULL
reduced	NULL
StatSa	NULL
$	NULL
726	NULL
phosphorylation	NULL
without	NULL
affecting	NULL
total	NULL
StatSa	NULL
protein	NULL
levels	NULL
(	NULL
Zanes	NULL
g	NULL
and	NULL
A	NULL
)	NULL
.	NULL

AG-490	NULL
disrupts	NULL
basal	NULL
and	NULL
IL-15-inducible	NULL
Jak3	NULL
,	NULL
Stat5a	NULL
,	NULL
and	NULL
Stat5b	NULL
tyrosine	NULL
phosphorylation	NULL
It	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
that	NULL
HuT-102	NULL
produces	NULL
high	NULL
levels	NULL
of	NULL
the	NULL
IL-15	NULL
mRNA	NULL
transcript	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
nearly	NULL
undetectable	NULL
levels	NULL
in	NULL
resting	NULL
or	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Bamford	NULL
et	NULL
al	NULL
.	NULL

(	NULL
51	NULL
)	NULL
found	NULL
that	NULL
the	NULL
R	NULL
region	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
HTLV-1	NULL
,	NULL
is	NULL
fused	NULL
with	NULL
the	NULL
IL-15	NULL
transcript	NULL
via	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
untranslated	NULL
region	NULL
,	NULL
driving	NULL
its	NULL
transcription	NULL
and	NULL
possibly	NULL
promoting	NULL
cell	NULL
proliferation	NULL
via	NULL
an	NULL
autocrine	NULL
regulated	NULL
loop	NULL
.	NULL

IL-15	NULL
,	NULL
like	NULL
IL-2	NULL
,	NULL
uses	NULL
the	NULL
IL-2RB	NULL
and	NULL
y_-chains	NULL
to	NULL
activate	NULL
Jak3	NULL
and	NULL
Stat5	NULL
;	NULL
thus	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
AG-490	NULL
could	NULL
also	NULL
disrupt	NULL
stimulation	NULL
of	NULL
Jak3/StatSa/b	NULL
by	NULL
exogenously	NULL
added	NULL
IL-15	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
,	NULL
IL-15	NULL
increased	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
StatSa	NULL
(	NULL
lanes	NULL
e	NULL
and	NULL
f	NULL
)	NULL
and	NULL
StatSb	NULL
(	NULL
lanes	NULL
i	NULL
and	NULL
J	NULL
)	NULL
over	NULL
basal	NULL
levels	NULL
,	NULL
but	NULL
not	NULL
that	NULL
of	NULL
Jak3	NULL
(	NULL
lanes	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
pretreatment	NULL
of	NULL
HuT-102	NULL
cells	NULL
with	NULL
AG-490	NULL
(	NULL
75	NULL
uM	NULL
)	NULL
completely	NULL
abolished	NULL
basal	NULL
and	NULL
IL-15-mediated	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
all	NULL
three	NULL
signaling	NULL
proteins	NULL
(	NULL
Zanes	NULL
c	NULL
,	NULL
d	NULL
,	NULL
g	NULL
,	NULL
A	NULL
,	NULL
k	NULL
,	NULL
and	NULL
/	NULL
)	NULL
.	NULL

Normalization	NULL
of	NULL
Jak3	NULL
and	NULL
StatSa/b	NULL
phosphotyrosine	NULL
levels	NULL
compared	NULL
with	NULL
total	NULL
protein	NULL
indicated	NULL
>	NULL
70	NULL
%	NULL
loss	NULL
of	NULL
phosphorylation	NULL
signal	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5100	NULL
FIGURE	NULL
2	NULL
.	NULL

AG-490	NULL
inhibits	NULL
constitutive	NULL
and	NULL
IL-15-inducible	NULL
tyrosine-phosphorylated	NULL
forms	NULL
of	NULL
StatSa	NULL
,	NULL
StatSb	NULL
,	NULL
and	NULL
Jak3	NULL
in	NULL
HuT-102	NULL
cells	NULL
.	NULL

Upper	NULL
panel	NULL
,	NULL
HuT-102	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
DMSO	NULL
(	NULL
control	NULL
)	NULL
or	NULL
75	NULL
uM	NULL
AG-490	NULL
for	NULL
16	NULL
h	NULL
and	NULL
stimulated	NULL
for	NULL
10	NULL
min	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
100	NULL
nM	NULL
IL-15	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
then	NULL
immunoprecipitated	NULL
with	NULL
anti-Jak3	NULL
(	NULL
lanes	NULL
a-d	NULL
)	NULL
,	NULL
StatSa	NULL
(	NULL
lanes	NULL
e-h	NULL
)	NULL
,	NULL
or	NULL
StatSb	NULL
(	NULL
lanes	NULL
i-1	NULL
)	NULL
and	NULL
blotted	NULL
with	NULL
antiphosphotyrosine	NULL
.	NULL

Lower	NULL
panel	NULL
,	NULL
Reblot	NULL
of	NULL
the	NULL
Western	NULL
blot	NULL
presented	NULL
above	NULL
that	NULL
had	NULL
been	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
Abs	NULL
directed	NULL
to	NULL
Jak3	NULL
,	NULL
StatSa	NULL
,	NULL
or	NULL
StatSb	NULL
to	NULL
examine	NULL
expression	NULL
levels	NULL
.	NULL

Molecular	NULL
weight	NULL
markers	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
left	NULL
,	NULL
and	NULL
arrows	NULL
denote	NULL
Jak3	NULL
or	NULL
l	NULL
StatSa/b	NULL
.	NULL

IP	NULL
:	NULL
kDa	NULL
a	NULL
IL15	NULL
:	NULL
=	NULL
l	NULL
Treatment	NULL
:	NULL
AG-490	NULL
inhibits	NULL
constitutive	NULL
and	NULL
IL-2-induced	NULL
activation	NULL
of	NULL
Stat5a/b	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
nuclear	NULL
cell	NULL
extracts	NULL
,	NULL
but	NULL
not	NULL
NFB	NULL
Jak-mediated	NULL
Stat	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
required	NULL
for	NULL
dimer-ization	NULL
,	NULL
disengagement	NULL
from	NULL
the	NULL
receptor	NULL
,	NULL
nuclear	NULL
translocation	NULL
,	NULL
and	NULL
subsequent	NULL
gene	NULL
transcription	NULL
(	NULL
19	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
idea	NULL
that	NULL
AG490	NULL
inhibits	NULL
the	NULL
generation	NULL
of	NULL
transcriptionally	NULL
competent	NULL
Stat5a/b	NULL
,	NULL
gel	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
used	NULL
to	NULL
assess	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
an	NULL
oligonucleotide	NULL
probe	NULL
corresponding	NULL
to	NULL
the	NULL
Stat5	NULL
binding	NULL
element	NULL
of	NULL
the	NULL
B-casein	NULL
gene	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
isolated	NULL
from	NULL
tyrphostin-treated	NULL
HuT-102	NULL
,	NULL
MT-2	NULL
,	NULL
or	NULL
PHA-activated	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
harvested	NULL
from	NULL
samples	NULL
identical	NULL
with	NULL
those	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
incubated	NULL
with	NULL
°°P-labeled	NULL
B-casein	NULL
probe	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
specific	NULL
Stat5a/b	NULL
antisera	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Extracts	NULL
from	NULL
IL-2-stimulated	NULL
cells	NULL
treated	NULL
overnight	NULL
with	NULL
DMSO	NULL
displayed	NULL
a	NULL
weakly	NULL
inducible	NULL
,	NULL
single	NULL
DNA	NULL
binding	NULL
complex	NULL
that	NULL
could	NULL
be	NULL
supershifted	NULL
with	NULL
anti-Stat5a	NULL
(	NULL
lane	NULL
c	NULL
)	NULL
,	NULL
partially	NULL
with	NULL
anti-Stat5b	NULL
(	NULL
lane	NULL
d	NULL
)	NULL
,	NULL
or	NULL
completely	NULL
with	NULL
both	NULL
StatSa	NULL
and	NULL
StatSb	NULL
Abs	NULL
(	NULL
lane	NULL
e	NULL
)	NULL
,	NULL
but	NULL
not	NULL
with	NULL
normal	NULL
rabbit	NULL
sera	NULL
alone	NULL
(	NULL
lane	NULL
f	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
all	NULL
transcription	NULL
factors	NULL
were	NULL
equally	NULL
inhibited	NULL
by	NULL
AG-490	NULL
in	NULL
HTLV-1-transformed	NULL
cells	NULL
,	NULL
the	NULL
non-Jak3-activating	NULL
pathway	NULL
,	NULL
TNF-a	NULL
,	NULL
was	NULL
examined	NULL
.	NULL

Cells	NULL
:	NULL
-	NULL
a	NULL
b	NULL
oc	NULL
d	NULL
e	NULL
f	NULL
g	NULL
h	NULL
i	NULL
J	NULL
k	NULL
I	NULL
+	NULL
th	NULL
«	NULL
0	NULL
»	NULL
wate	NULL
-	NULL
>	NULL
HuT-102	NULL
H	NULL
“	NULL
®	NULL
!	NULL

H	NULL
#	NULL
B	NULL
»	NULL
.	NULL

gat	NULL
brut	NULL
fud	NULL
MT-2	NULL
Human	NULL
T	NULL
Cells	NULL
IL2	NULL
:	NULL
=	NULL
o	NULL
$	NULL
o	NULL
$	NULL
#	NULL
$	NULL
4	NULL
4	NULL
a	NULL
Stat5	NULL
:	NULL
|T	NULL
_	NULL
``	NULL
a	NULL
b	NULL
ab	NULL
nre	NULL
jj	NULL
``	NULL
___	NULL
``	NULL
a	NULL
Treatment	NULL
:	NULL
DMSO	NULL
t+	NULL
4	NULL
+0	NULL
4+	NULL
+	NULL
#	NULL
b	NULL
a/b	NULL
nrs	NULL
AG-490	NULL
DMSO	NULL
HTLV-1	NULL
TRANSFORMATION	NULL
DOES	NULL
NOT	NULL
REQUIRE	NULL
JAK3/STATS5	NULL
PATHWAY	NULL
WB	NULL
:	NULL
a	NULL
PY	NULL
a	NULL
Jak3	NULL
a	NULL
Stat5	NULL
AG490	NULL
DMSO	NULL
w	NULL
o	NULL
Stat5a	NULL
AG490	NULL
DMSO	NULL
AG490	NULL
J	NULL
L	NULL
]	NULL
a	NULL
Jak3	NULL
o	NULL
Stat5b	NULL
For	NULL
this	NULL
study	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
HuT-102	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
,	NULL
MT-2	NULL
(	NULL
middle	NULL
panel	NULL
)	NULL
,	NULL
or	NULL
PHA-activated	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
vehicle	NULL
(	NULL
lanes	NULL
a-e	NULL
)	NULL
or	NULL
AG-490	NULL
(	NULL
lanes	NULL
-j	NULL
)	NULL
and	NULL
stimulated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Janes	NULL
a	NULL
and	NULL
f	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
(	NULL
b-e	NULL
and	NULL
g-7	NULL
)	NULL
of	NULL
100	NULL
nM	NULL
TNF-a	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Next	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
cell	NULL
extract	NULL
from	NULL
each	NULL
sample	NULL
set	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
element	NULL
and	NULL
supershifted	NULL
with	NULL
the	NULL
appropriate	NULL
Ab	NULL
to	NULL
confirm	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
p50/p65	NULL
complex	NULL
.	NULL

AG-490	NULL
was	NULL
not	NULL
effective	NULL
at	NULL
inhibiting	NULL
constitutive	NULL
or	NULL
cytokine-inducible	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
a-J	NULL
)	NULL
.	NULL

AG-490	NULL
blocks	NULL
IL-2-mediated	NULL
growth	NULL
of	NULL
mitogen-activated	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
HTLV-1-transformed	NULL
cells	NULL
Since	NULL
the	NULL
Jak3/Stat5	NULL
pathway	NULL
is	NULL
known	NULL
to	NULL
promote	NULL
T	NULL
cell	NULL
growth	NULL
,	NULL
we	NULL
next	NULL
tested	NULL
whether	NULL
AG-490	NULL
could	NULL
effectively	NULL
block	NULL
leukemic	NULL
cell	NULL
growth	NULL
of	NULL
HTLV-1-transformed	NULL
cells	NULL
(	NULL
26	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Previously	NULL
studies	NULL
indicated	NULL
that	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
AG-490	NULL
were	NULL
>	NULL
90	NULL
%	NULL
viable	NULL
,	NULL
and	NULL
inhibition	NULL
of	NULL
IL-2-inducible	NULL
cell	NULL
proliferation	NULL
was	NULL
recoverable	NULL
(	NULL
43	NULL
)	NULL
.	NULL

For	NULL
these	NULL
experiments	NULL
,	NULL
actively	NULL
growing	NULL
PHA-activated	NULL
T	NULL
cells	NULL
,	NULL
HuT-102	NULL
,	NULL
or	NULL
MT-2	NULL
cells	NULL
were	NULL
cocultured	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
drug	NULL
for	NULL
a	NULL
period	NULL
of	NULL
16	NULL
h	NULL
and	NULL
assayed	NULL
FIGURE	NULL
3	NULL
.	NULL

Pretreatment	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
or	NULL
HTLV-1	NULL
transformed	NULL
HuT-102	NULL
or	NULL
MT-2	NULL
cells	NULL
with	NULL
AG490	NULL
inhibits	NULL
constitutive	NULL
and	NULL
IL-2-induced	NULL
StatSa/b	NULL
DNA	NULL
binding	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
EMSA	NULL
analysis	NULL
.	NULL

Lower	NULL
panel	NULL
,	NULL
PHA-activated	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
with	NULL
either	NULL
DMSO	NULL
(	NULL
control	NULL
;	NULL
lanes	NULL
a-f	NULL
)	NULL
or	NULL
75	NULL
uM	NULL
AG-490	NULL
(	NULL
lanes	NULL
j-	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
medium	NULL
(	NULL
-	NULL
)	NULL
or	NULL
100	NULL
nM	NULL
IL-2	NULL
(	NULL
+	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

MT-2	NULL
(	NULL
middle	NULL
panel	NULL
)	NULL
or	NULL
HuT-102	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
cells	NULL
were	NULL
treated	NULL
similarly	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
corresponding	NULL
to	NULL
5	NULL
ug	NULL
of	NULL
protein	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ab	NULL
(	NULL
lanes	NULL
a	NULL
,	NULL
b	NULL
,	NULL
g	NULL
,	NULL
and	NULL
h	NULL
)	NULL
or	NULL
with	NULL
e-StatSa	NULL
(	NULL
lanes	NULL
c	NULL
and	NULL
1	NULL
)	NULL
,	NULL
a-StatSb	NULL
(	NULL
lanes	NULL
d	NULL
and	NULL
f	NULL
)	NULL
,	NULL
e-StatSb	NULL
and	NULL
a-StatSa	NULL
(	NULL
lanes	NULL
e	NULL
and	NULL
k	NULL
)	NULL
,	NULL
or	NULL
normal	NULL
rabbit	NULL
serum	NULL
(	NULL
Zanes	NULL
e	NULL
and	NULL
j	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
*°P-labeled	NULL
oligonucleotide	NULL
probe	NULL
corresponding	NULL
to	NULL
the	NULL
PRL	NULL
response	NULL
element	NULL
of	NULL
the	NULL
B-casein	NULL
gene	NULL
promoter	NULL
.	NULL

Migrational	NULL
location	NULL
of	NULL
nonsupershifted	NULL
StatSa/b	NULL
DNA	NULL
complexes	NULL
before	NULL
Ab	NULL
addition	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
on	NULL
the	NULL
right	NULL
.	NULL

<	NULL
-	NULL
StatSa/b	NULL
-	NULL
<	NULL
+-	NULL
Stat5a/b	NULL
<	NULL
-	NULL
Stat5a/b	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Cell	NULL
:	NULL
HuT-102	NULL
FIGURE	NULL
4	NULL
.	NULL

AG-490	NULL
fails	NULL
to	NULL
inhibit	NULL
constitutive	NULL
or	NULL
TNF-	NULL
«	NULL
-inducible	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
HuT-102	NULL
and	NULL
MT-2	NULL
cells	NULL
HTLV-l-transformed	NULL
HuT-102	NULL
cells	NULL
(	NULL
fop	NULL
panel	NULL
)	NULL
,	NULL
MT-2	NULL
(	NULL
middle	NULL
panel	NULL
)	NULL
,	NULL
or	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
DMSO	NULL
(	NULL
lanes	NULL
a-e	NULL
)	NULL
or	NULL
75	NULL
wM	NULL
AG-490	NULL
(	NULL
lanes	NULL
f-	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
medium	NULL
(	NULL
-	NULL
)	NULL
or	NULL
100	NULL
nM	NULL
TNF-	NULL
«	NULL
(	NULL
+	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
and	NULL
then	NULL
subjected	NULL
to	NULL
DNA	NULL
binding	NULL
analysis	NULL
using	NULL
a	NULL
radiolabeled	NULL
probe	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

For	NULL
this	NULL
assay	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
cell	NULL
extracts	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Janes	NULL
a	NULL
,	NULL
b	NULL
,	NULL
f	NULL
,	NULL
and	NULL
g	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
Ab	NULL
to	NULL
p50	NULL
(	NULL
e-p50	NULL
;	NULL
lanes	NULL
c	NULL
and	NULL
A	NULL
)	NULL
,	NULL
anti-p65	NULL
(	NULL
e-p65	NULL
;	NULL
lanes	NULL
d	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
normal	NULL
rabbit	NULL
serum	NULL
(	NULL
lanes	NULL
e	NULL
and	NULL
j	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
°°P-labeled	NULL
oligonucleotide	NULL
probe	NULL
corresponding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
element	NULL
(	NULL
Janes	NULL
a-7	NULL
)	NULL
.	NULL

Migrational	NULL
location	NULL
of	NULL
the	NULL
nonsupershifted	NULL
(	NULL
without	NULL
Ab	NULL
)	NULL
p50/p60	NULL
TNF-a	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
complex	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
on	NULL
the	NULL
right	NULL
.	NULL

MT-2	NULL
Human	NULL
T	NULL
Cells	NULL
TNF	NULL
a	NULL
:	NULL
NFkB	NULL
Ab	NULL
:	NULL
Treatment	NULL
:	NULL
for	NULL
newly	NULL
synthesized	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

AG-490	NULL
completely	NULL
abolished	NULL
IL-2-inducible	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
into	NULL
PHA-activated	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
at	NULL
50	NULL
wM	NULL
,	NULL
displaying	NULL
a	NULL
50	NULL
%	NULL
inhibitory	NULL
concentration	NULL
of	NULL
approximately	NULL
20	NULL
wM	NULL
while	NULL
having	NULL
no	NULL
effect	NULL
on	NULL
either	NULL
HuT-102	NULL
or	NULL
MT-2	NULL
cells	NULL
,	NULL
even	NULL
at	NULL
concentrations	NULL
as	NULL
high	NULL
as	NULL
100	NULL
uM	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
we	NULL
consistently	NULL
observed	NULL
enhanced	NULL
thy-midine	NULL
uptake	NULL
in	NULL
HTLV-1-transformed	NULL
cells	NULL
treated	NULL
with	NULL
this	NULL
tyr-phostin	NULL
,	NULL
particularly	NULL
HuT-102	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
AG-490	NULL
potently	NULL
inhibited	NULL
basal	NULL
and	NULL
cytokine-induced	NULL
Jak3/Stat5a/b	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
Stat5a/b	NULL
DNA	NULL
binding	NULL
,	NULL
it	NULL
failed	NULL
to	NULL
block	NULL
malignant	NULL
cell	NULL
growth	NULL
of	NULL
HTLV-1-transformed	NULL
cell	NULL
lines	NULL
.	NULL

AG-490	NULL
belongs	NULL
to	NULL
a	NULL
family	NULL
of	NULL
relatively	NULL
uncharacterized	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
,	NULL
originally	NULL
derived	NULL
from	NULL
benzylidine	NULL
mal-ononitrile	NULL
,	NULL
that	NULL
structurally	NULL
mimic	NULL
tyrosine	NULL
and	NULL
ATP	NULL
moieties	NULL
(	NULL
44	NULL
,	NULL
45	NULL
)	NULL
.	NULL

We	NULL
identified	NULL
five	NULL
tyrphostins	NULL
that	NULL
were	NULL
able	NULL
to	NULL
potently	NULL
inhibit	NULL
IL-2	NULL
stimulation	NULL
of	NULL
Jak3	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Their	NULL
specificity	NULL
was	NULL
not	NULL
studied	NULL
further	NULL
;	NULL
however	NULL
,	NULL
they	NULL
were	NULL
each	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
uptake	NULL
of	NULL
HTLV-1-transformed	NULL
and	NULL
PHA-activated	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

For	NULL
this	NULL
analysis	NULL
,	NULL
all	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
100	NULL
uM	NULL
of	NULL
the	NULL
indicated	NULL
drug	NULL
for	NULL
16	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
AG-490	NULL
,	NULL
all	NULL
five	NULL
tyrphostins	NULL
,	NULL
including	NULL
A25	NULL
,	NULL
B44	NULL
,	NULL
B46	NULL
,	NULL
B48	NULL
,	NULL
and	NULL
B50	NULL
,	NULL
potently	NULL
inhibited	NULL
primary	NULL
T	NULL
cell	NULL
growth	NULL
;	NULL
however	NULL
,	NULL
these	NULL
agents	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
HTLV-1-transformed	NULL
cells	NULL
.	NULL

Only	NULL
B46	NULL
showed	NULL
moderate	NULL
inhibitory	NULL
activity	NULL
in	NULL
Hut-102	NULL
cells	NULL
(	NULL
~40	NULL
%	NULL
)	NULL
,	NULL
but	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
MT-2	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
leukemic	NULL
human	NULL
NK	NULL
cell	NULL
line	NULL
YT	NULL
,	NULL
which	NULL
expresses	NULL
Jak3	NULL
but	NULL
is	NULL
not	NULL
HTLV-1	NULL
transformed	NULL
,	NULL
displayed	NULL
a	NULL
drug	NULL
sensitivity	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
PHA-activated	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
evidence	NULL
demonstrates	NULL
that	NULL
HTLV-1-transformed	NULL
cells	NULL
are	NULL
resistant	NULL
to	NULL
a	NULL
series	NULL
of	NULL
tyrphostins	NULL
and	NULL
suggests	NULL
that	NULL
HTLV-1	NULL
leukemogenesis	NULL
is	NULL
not	NULL
dependent	NULL
on	NULL
Jak2/Jak3/Stat5	NULL
activity	NULL
.	NULL

5101	NULL
ll	NULL
*	NULL
*	NULL
%	NULL
‘	NULL
i	NULL
‘	NULL
v	NULL
¢	NULL
UV	NULL
UUHU	NULL
WH	NULL
--	NULL
#	NULL
®	NULL
#	NULL
®	NULL
ibd	NULL
oth	NULL
bbd	NULL
(	NULL
obd	NULL
-	NULL
<	NULL
Hue	NULL
-_-	NULL
+o	NULL
4+	NULL
+	NULL
#	NULL
+	NULL
-	NULL
ap50	NULL
ap65	NULL
nrs	NULL
AG490	NULL
=-	NULL
o	NULL
$	NULL
404	NULL
#	NULL
=	NULL
1	NULL
``	NULL
-	NULL
ap50	NULL
ap65	NULL
nrs	NULL
“	NULL
.	NULL

DMSO	NULL
Discussion	NULL
In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
AG-490	NULL
blocks	NULL
constitutive	NULL
and	NULL
IL-2/IL-15-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat5a/b	NULL
isolated	NULL
from	NULL
HTLV-1-transformed	NULL
MT-2	NULL
and	NULL
HuT-102	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

We	NULL
also	NULL
provide	NULL
the	NULL
first	NULL
account	NULL
that	NULL
HTLV-1-transformed	NULL
cells	NULL
display	NULL
constitutive	NULL
serine-phosphory-lated	NULL
StatSa	NULL
(	NULL
S726	NULL
)	NULL
,	NULL
but	NULL
not	NULL
StatSb	NULL
,	NULL
and	NULL
that	NULL
this	NULL
kinase	NULL
was	NULL
efficiently	NULL
blocked	NULL
by	NULL
AG-490	NULL
,	NULL
most	NULL
likely	NULL
via	NULL
inhibition	NULL
of	NULL
its	NULL
far	NULL
upstream	NULL
activator	NULL
,	NULL
Jak3	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

EMSA	NULL
analysis	NULL
further	NULL
verified	NULL
that	NULL
DNA	NULL
binding	NULL
of	NULL
partially	NULL
purified	NULL
StatSa/b	NULL
harvested	NULL
from	NULL
actively	NULL
growing	NULL
or	NULL
cytokine-stimulated	NULL
MT-2	NULL
or	NULL
HuT-102	NULL
cells	NULL
was	NULL
significantly	NULL
inhibited	NULL
following	NULL
AG-490	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
drug	NULL
had	NULL
no	NULL
overt	NULL
effect	NULL
on	NULL
constitutive	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
isolated	NULL
from	NULL
similarly	NULL
treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
Jak3/StatSa/b	NULL
signaling	NULL
pathway	NULL
by	NULL
AG-490	NULL
failed	NULL
to	NULL
disrupt	NULL
leukemic	NULL
growth	NULL
of	NULL
HTLV-1-transformed	NULL
cells	NULL
.	NULL

Similarly	NULL
,	NULL
several	NULL
other	NULL
potent	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
were	NULL
competent	NULL
to	NULL
block	NULL
basal	NULL
and	NULL
IL-2-stimulated	NULL
cell	NULL
growth	NULL
of	NULL
mitogen-activated	NULL
lymphocytes	NULL
,	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
HTLV-1-transformed	NULL
cells	NULL
(	NULL
Figs	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Jak	NULL
and	NULL
Stat	NULL
proteins	NULL
have	NULL
received	NULL
much	NULL
attention	NULL
as	NULL
putative	NULL
targets	NULL
for	NULL
controlling	NULL
leukemogenesis	NULL
.	NULL

Indeed	NULL
,	NULL
constitutively	NULL
activated	NULL
Jak	NULL
and	NULL
Stat	NULL
proteins	NULL
have	NULL
been	NULL
identified	NULL
and	NULL
studied	NULL
in	NULL
several	NULL
distinct	NULL
oncogenic	NULL
models	NULL
,	NULL
including	NULL
a	NULL
leukemia-like	NULL
phenotype	NULL
in	NULL
Drosophila	NULL
(	NULL
52	NULL
)	NULL
,	NULL
B	NULL
cell	NULL
Ag	NULL
receptor-Abl-expressing	NULL
cell	NULL
lines	NULL
and	NULL
patient	NULL
peripheral	NULL
lymphocytes	NULL
(	NULL
40	NULL
)	NULL
,	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
blasts	NULL
(	NULL
53	NULL
)	NULL
,	NULL
B	NULL
lymphocytes	NULL
obtained	NULL
from	NULL
patients	NULL
afflicted	NULL
with	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
54	NULL
)	NULL
,	NULL
EBV-infected	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
src-transformed	NULL
cells	NULL
(	NULL
35-39	NULL
)	NULL
.	NULL

The	NULL
explanation	NULL
of	NULL
how	NULL
the	NULL
HTLV-1	NULL
virus	NULL
transforms	NULL
T	NULL
cells	NULL
to	NULL
a	NULL
state	NULL
of	NULL
growth	NULL
factor	NULL
independence	NULL
is	NULL
not	NULL
readily	NULL
apparent	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
known	NULL
that	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5102	NULL
HTLV-1	NULL
TRANSFORMATION	NULL
DOES	NULL
NOT	NULL
REQUIRE	NULL
JAK3/STATS5	NULL
PATHWAY	NULL
1200004	NULL
T	NULL
Cells	NULL
100000-800004	NULL
s00004	NULL
400004	NULL
200004	NULL
o	NULL
0	NULL
2	NULL
&	NULL
5	NULL
5	NULL
40	NULL
25	NULL
50	NULL
75	NULL
100	NULL
HuT-102	NULL
0	NULL
25	NULL
5	NULL
do	NULL
as	NULL
50	NULL
750	NULL
100	NULL
MT-2	NULL
50004	NULL
[	NULL
BH	NULL
]	NULL
-Thymidine	NULL
Incorporation	NULL
(	NULL
cpm	NULL
)	NULL
4000	NULL
4	NULL
3000	NULL
4	NULL
2000	NULL
4	NULL
1000	NULL
4	NULL
0	NULL
25	NULL
s	NULL
10	NULL
250	NULL
50	NULL
75	NULL
100	NULL
Tyrphostin	NULL
AG-490	NULL
(	NULL
uM	NULL
)	NULL
FIGURE	NULL
5	NULL
.	NULL

AG-490	NULL
inhibits	NULL
IL-2-induced	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
but	NULL
not	NULL
HTLV-1-transformed	NULL
HuT-102	NULL
or	NULL
MT-2	NULL
cell	NULL
lines	NULL
.	NULL

Top	NULL
panel	NULL
,	NULL
Cell	NULL
proliferation	NULL
of	NULL
PHA-activated	NULL
,	NULL
quiescent	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10*/well	NULL
)	NULL
was	NULL
examined	NULL
following	NULL
treatment	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
AG-490	NULL
(	NULL
ordinate	NULL
)	NULL
for	NULL
16	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
nM	NULL
IL-2	NULL
,	NULL
except	NULL
for	NULL
the	NULL
sample	NULL
represented	NULL
by	NULL
the	NULL
first	NULL
bar	NULL
.	NULL

Similarly	NULL
,	NULL
HuT-102	NULL
(	NULL
middle	NULL
panel	NULL
)	NULL
and	NULL
MT-2	NULL
cells	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
or	NULL
AG-490	NULL
as	NULL
indicated	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
then	NULL
pulsed	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
(	NULL
0.5	NULL
Ci/200	NULL
pul	NULL
)	NULL
for	NULL
4	NULL
h	NULL
,	NULL
and	NULL
incorporation	NULL
of	NULL
radiolabel	NULL
is	NULL
plotted	NULL
on	NULL
the	NULL
abscissa	NULL
,	NULL
expressed	NULL
as	NULL
total	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
SEM	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
.	NULL

infected	NULL
T	NULL
cell	NULL
cultures	NULL
become	NULL
IL-2	NULL
independent	NULL
over	NULL
time	NULL
,	NULL
which	NULL
parallels	NULL
acquisition	NULL
of	NULL
constitutively	NULL
active	NULL
Jak3	NULL
,	NULL
but	NULL
not	NULL
Jak2	NULL
,	NULL
Jak1	NULL
,	NULL
or	NULL
Tyk2	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
lymphocytes	NULL
obtained	NULL
from	NULL
HTLV-l-infected	NULL
patients	NULL
display	NULL
constitutively	NULL
active	NULL
Stat	NULL
proteins	NULL
,	NULL
which	NULL
also	NULL
correlates	NULL
with	NULL
enhanced	NULL
Jak3	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Since	NULL
Jak3	NULL
is	NULL
only	NULL
recruited	NULL
and	NULL
activated	NULL
by	NULL
T	NULL
cell	NULL
growth	NULL
factors	NULL
that	NULL
use	NULL
y	NULL
,	NULL
,	NULL
,	NULL
autocrine-regulated	NULL
growth	NULL
by	NULL
one	NULL
or	NULL
more	NULL
of	NULL
these	NULL
cytokines	NULL
has	NULL
been	NULL
proposed	NULL
(	NULL
34	NULL
)	NULL
.	NULL

An	NULL
autocrine-regulated	NULL
loop	NULL
for	NULL
IL-2	NULL
or	NULL
IL-15	NULL
was	NULL
mostly	NULL
dispelled	NULL
,	NULL
since	NULL
coculturing	NULL
cells	NULL
with	NULL
respective	NULL
Abs	NULL
failed	NULL
to	NULL
disrupt	NULL
malignant	NULL
cell	NULL
growth	NULL
or	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak	NULL
and	NULL
Stat	NULL
proteins	NULL
;	NULL
however	NULL
,	NULL
other	NULL
Jak3-activating	NULL
cytokines	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
IL-4	NULL
or	NULL
IL-7	NULL
)	NULL
could	NULL
not	NULL
be	NULL
excluded	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
AG-490	NULL
potently	NULL
inhibits	NULL
constitutive	NULL
Jak3	NULL
activity	NULL
.	NULL

Previously	NULL
we	NULL
reported	NULL
that	NULL
this	NULL
tyrphostin	NULL
selectively	NULL
inhibits	NULL
IL-2-induced	NULL
autophosphorylation	NULL
of	NULL
Jak3	NULL
following	NULL
in	NULL
vivo	NULL
or	NULL
direct	NULL
in	NULL
vitro	NULL
treatment	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
stimulation	NULL
of	NULL
Jak3	NULL
by	NULL
the	NULL
other	NULL
y.	NULL
cytokines	NULL
(	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-9	NULL
,	NULL
and	NULL
IL-15	NULL
)	NULL
was	NULL
profoundly	NULL
blocked	NULL
at	NULL
concentrations	NULL
of	NULL
AG-490	NULL
similar	NULL
to	NULL
those	NULL
used	NULL
here	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Since	NULL
proliferation	NULL
assays	NULL
failed	NULL
to	NULL
detect	NULL
any	NULL
disruption	NULL
in	NULL
cell	NULL
growth	NULL
of	NULL
MT-2	NULL
or	NULL
HuT-102	NULL
following	NULL
treatment	NULL
with	NULL
AG-490	NULL
(	NULL
Figs	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Jak3-mediated	NULL
pathways	NULL
are	NULL
unlikely	NULL
to	NULL
perpetuate	NULL
HTLV-1	NULL
malignancy	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
whether	NULL
the	NULL
cycle	NULL
of	NULL
HTLV-1	NULL
leukemogenesis	NULL
may	NULL
prove	NULL
susceptible	NULL
to	NULL
Jak3	NULL
inhibitors	NULL
during	NULL
the	NULL
immortalization	NULL
phase	NULL
(	NULL
ligand	NULL
dependent	NULL
)	NULL
,	NULL
before	NULL
transformation	NULL
(	NULL
ligand	NULL
independent	NULL
)	NULL
,	NULL
where	NULL
cumulative	NULL
genetic	NULL
errors	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
manifested	NULL
as	NULL
neoplastic	NULL
T	NULL
cell	NULL
growth	NULL
.	NULL

While	NULL
HTLV-1-mediated	NULL
IL-2	NULL
independence	NULL
requires	NULL
a	NULL
6-	NULL
to	NULL
12-mo	NULL
latency	NULL
period	NULL
(	NULL
8-11	NULL
)	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
pretreatment	NULL
of	NULL
mitogen-activated	NULL
or	NULL
unactivated	NULL
T	NULL
cells	NULL
with	NULL
25000	NULL
T	NULL
Cells	NULL
30000	NULL
25000	NULL
20000	NULL
15000	NULL
10000	NULL
5000	NULL
``	NULL
a=	NULL
0-	NULL
+	NULL
+	NULL
+	NULL
[	NULL
3	NULL
]	NULL
112	NULL
:	NULL
~	NULL
100548	NULL
~	NULL
mo	NULL
tic	NULL
tz	NULL
a	NULL
.	NULL

$	NULL
gO	NULL
of	NULL
f	NULL
|	NULL
f	NULL
F4	NULL
a	NULL
<	NULL
c	NULL
t	NULL
m	NULL
m	NULL
ta	NULL
8	NULL
$	NULL
5000	NULL
g	NULL
HuT-102	NULL
-	NULL
4000	NULL
``	NULL
5	NULL
0	NULL
e	NULL
3000	NULL
fe	NULL
]	NULL
(	NULL
4	NULL
)	NULL
C	NULL
2000	NULL
©	NULL
&	NULL
»	NULL
£	NULL
o	NULL
Bm	NULL
=	NULL
12	NULL
:	NULL
ct	NULL
cic	NULL
ctc	NULL
zn	NULL
ctr	NULL
cti	NULL
cti	NULL
£	NULL
g	NULL
Os	NULL
i	NULL
Gg	NULL
Gf	NULL
f	NULL
f	NULL
P	NULL
=	NULL
G	NULL
&	NULL
t	NULL
[	NULL
[	NULL
4	NULL
]	NULL
ron	NULL
o	NULL
_	NULL
<	NULL
10000	NULL
fnmud	NULL
8000	NULL
1	NULL
6000	NULL
4000	NULL
2000	NULL
0	NULL
12	NULL
:	NULL
tot	NULL
n	NULL
hn	NULL
tit	NULL
t	NULL
t	NULL
hat	NULL
hut	NULL
o*	NULL
g	NULL
&	NULL
a	NULL
Fa	NULL
$	NULL
$	NULL
&	NULL
&	NULL
pa	NULL
<	NULL
m	NULL
m	NULL
F3	NULL
E	NULL
=	NULL
a	NULL
a	NULL
<	NULL
FIGURE	NULL
6	NULL
.	NULL

-	NULL
Various	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
ablate	NULL
cell	NULL
growth	NULL
of	NULL
mitogen-activated	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
HuT-102	NULL
or	NULL
MT-2	NULL
cells	NULL
.	NULL

Top	NULL
panel	NULL
,	NULL
Proliferation	NULL
of	NULL
PHA-activated	NULL
,	NULL
quiescent	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10*/well	NULL
)	NULL
was	NULL
examined	NULL
following	NULL
treatment	NULL
with	NULL
tyrphostin-derived	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
.	NULL

PHA-activated	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
HuT-102	NULL
cells	NULL
,	NULL
and	NULL
MT-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
100	NULL
M	NULL
AG-490	NULL
,	NULL
A25	NULL
,	NULL
B44	NULL
,	NULL
B46	NULL
,	NULL
B48	NULL
,	NULL
or	NULL
B50	NULL
for	NULL
16	NULL
h	NULL
at	NULL
37°C	NULL
(	NULL
ordinate	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
then	NULL
pulsed	NULL
with	NULL
[	NULL
°HJthymidine	NULL
(	NULL
0.5	NULL
Ci/200	NULL
pl	NULL
)	NULL
for	NULL
4	NULL
h	NULL
,	NULL
and	NULL
incorporation	NULL
of	NULL
radiolabeled	NULL
probe	NULL
is	NULL
plotted	NULL
on	NULL
the	NULL
abscissa	NULL
,	NULL
expressed	NULL
as	NULL
total	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
SEM	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
.	NULL

varying	NULL
concentrations	NULL
of	NULL
AG-490	NULL
resulted	NULL
in	NULL
T	NULL
cell	NULL
death	NULL
after	NULL
5-7	NULL
days	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
ablation	NULL
of	NULL
all	NULL
anti-apoptotic	NULL
T	NULL
cell	NULL
growth	NULL
factors	NULL
that	NULL
signal	NULL
via	NULL
Jak3	NULL
does	NULL
not	NULL
make	NULL
such	NULL
an	NULL
analysis	NULL
readily	NULL
addressable	NULL
.	NULL

Can	NULL
HTLV-1	NULL
promote	NULL
oncogenesis	NULL
by	NULL
non-Jak	NULL
tyrosine	NULL
kinases	NULL
?	NULL

A	NULL
recent	NULL
report	NULL
found	NULL
that	NULL
human	NULL
T	NULL
cells	NULL
transformed	NULL
by	NULL
herpesvirus	NULL
saimiri	NULL
display	NULL
constitutively	NULL
activated	NULL
Zap70	NULL
and	NULL
p56	NULL
``	NULL
*	NULL
,	NULL
but	NULL
not	NULL
Jak	NULL
or	NULL
Stat	NULL
proteins	NULL
(	NULL
55	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Upon	NULL
further	NULL
investigation	NULL
,	NULL
we	NULL
failed	NULL
to	NULL
detect	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
either	NULL
protein	NULL
in	NULL
MT-2	NULL
or	NULL
HuT-102	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
several	NULL
of	NULL
the	NULL
more	NULL
broadly	NULL
based	NULL
tyrphostins	NULL
(	NULL
A25	NULL
,	NULL
B44	NULL
,	NULL
B46	NULL
,	NULL
B48	NULL
,	NULL
and	NULL
B50	NULL
)	NULL
,	NULL
which	NULL
also	NULL
inhibited	NULL
Jak3	NULL
(	NULL
R.	NULL
A.	NULL
Kirken	NULL
,	NULL
unpublished	NULL
observation	NULL
)	NULL
might	NULL
be	NULL
expected	NULL
to	NULL
have	NULL
an	NULL
effect	NULL
on	NULL
the	NULL
hyperactivation	NULL
of	NULL
additional	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Nonetheless	NULL
,	NULL
all	NULL
five	NULL
agents	NULL
blocked	NULL
both	NULL
basal	NULL
and	NULL
IL-2-induced	NULL
proliferation	NULL
of	NULL
PHA-activated	NULL
T	NULL
cells	NULL
,	NULL
while	NULL
only	NULL
B46	NULL
showed	NULL
moderate	NULL
inhibition	NULL
(	NULL
~40	NULL
%	NULL
)	NULL
at	NULL
100-uM	NULL
concentrations	NULL
of	NULL
drug	NULL
in	NULL
HuT-102	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
this	NULL
response	NULL
was	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
not	NULL
observed	NULL
for	NULL
MT-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

From	NULL
this	NULL
evidence	NULL
we	NULL
conclude	NULL
that	NULL
tyrosine	NULL
kinases	NULL
in	NULL
general	NULL
may	NULL
not	NULL
play	NULL
a	NULL
predominant	NULL
role	NULL
in	NULL
the	NULL
leukemogenesis	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
40-kDa	NULL
phosphoprotein	NULL
Tax	NULL
does	NULL
not	NULL
bind	NULL
directly	NULL
to	NULL
DNA	NULL
;	NULL
however	NULL
,	NULL
it	NULL
is	NULL
responsible	NULL
for	NULL
driving	NULL
the	NULL
trans-activation	NULL
and	NULL
transcription	NULL
of	NULL
several	NULL
proliferative	NULL
genes	NULL
in	NULL
addition	NULL
to	NULL
HTLV-1	NULL
,	NULL
presumably	NULL
by	NULL
interacting	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
protein	NULL
factors	NULL
,	NULL
including	NULL
CREB/ATF	NULL
binding	NULL
proteins	NULL
,	NULL
p67°~	NULL
``	NULL
,	NULL
and	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p16	NULL
``	NULL
¢***	NULL
,	NULL
allowing	NULL
for	NULL
cyclin-dependent	NULL
kinase-4	NULL
activation	NULL
and	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
18	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
normally	NULL
sequestered	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
resting	NULL
T	NULL
lymphocytes	NULL
;	NULL
however	NULL
;	NULL
Tax	NULL
stimulates	NULL
the	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
IkB-a	NULL
and	NULL
via	NULL
two	NULL
conserved	NULL
serine	NULL
residues	NULL
that	NULL
allow	NULL
transcriptionally	NULL
active	NULL
NF-KB	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
promote	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
a-chain	NULL
(	NULL
14	NULL
)	NULL
,	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proto-oncogenes	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
Stat5	NULL
(	NULL
16	NULL
)	NULL
.	NULL

It	NULL
is	NULL
of	NULL
interest	NULL
to	NULL
note	NULL
that	NULL
these	NULL
signaling	NULL
pathways	NULL
are	NULL
predominantly	NULL
dependent	NULL
on	NULL
serine-threo-nine	NULL
,	NULL
and	NULL
not	NULL
tyrosine	NULL
kinase	NULL
,	NULL
activity	NULL
.	NULL

As	NULL
stated	NULL
above	NULL
,	NULL
several	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
failed	NULL
to	NULL
block	NULL
the	NULL
growth	NULL
of	NULL
HTLV-1-transformed	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Despite	NULL
potent	NULL
inhibition	NULL
of	NULL
StatSa/b	NULL
DNA	NULL
binding	NULL
by	NULL
AG-490	NULL
,	NULL
there	NULL
was	NULL
no	NULL
loss	NULL
of	NULL
constitutive	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
therapeutic	NULL
approaches	NULL
aimed	NULL
at	NULL
ablating	NULL
Tax/serine-threonine	NULL
kinase	NULL
signaling	NULL
molecules	NULL
may	NULL
hold	NULL
greater	NULL
potential	NULL
for	NULL
treating	NULL
this	NULL
disease	NULL
.	NULL

Whether	NULL
similar	NULL
observations	NULL
and	NULL
conclusions	NULL
will	NULL
be	NULL
encountered	NULL
for	NULL
other	NULL
leukemic	NULL
malignancies	NULL
displaying	NULL
hyperphosphorylated	NULL
Jak	NULL
and	NULL
Stat	NULL
signaling	NULL
proteins	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Mrs.	NULL
Terry	NULL
Williams	NULL
and	NULL
Barton	NULL
Trawick	NULL
for	NULL
expert	NULL
technical	NULL
help	NULL
with	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
figures	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Poiesz	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
F.	NULL
W.	NULL
Ruscetti	NULL
,	NULL
A.	NULL
F.	NULL
Gazdar	NULL
,	NULL
P.	NULL
A.	NULL
Bunn	NULL
,	NULL
J.	NULL
D.	NULL
Minna	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1980	NULL
.	NULL

Detection	NULL
and	NULL
isolation	NULL
of	NULL
type	NULL
C	NULL
retrovirus	NULL
particles	NULL
from	NULL
fresh	NULL
and	NULL
cultured	NULL
lymphocytes	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
cutancous	NULL
T-cell	NULL
lymphoma	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
77:7415	NULL
.	NULL

2	NULL
.	NULL

Miyoshi	NULL
,	NULL
I.	NULL
,	NULL
I.	NULL
Kubonishi	NULL
,	NULL
S.	NULL
Yoshimoto	NULL
,	NULL
T.	NULL
Akagi	NULL
,	NULL
Y.	NULL
Ohtsuki	NULL
,	NULL
Y.	NULL
Shiraishi	NULL
,	NULL
K.	NULL
Nagata	NULL
,	NULL
and	NULL
Y.	NULL
Hinuma	NULL
.	NULL

1981	NULL
.	NULL

Type	NULL
C	NULL
virus	NULL
particles	NULL
in	NULL
a	NULL
cord	NULL
T-cell	NULL
line	NULL
derived	NULL
by	NULL
co-cultivating	NULL
normal	NULL
human	NULL
cord	NULL
leukocytes	NULL
and	NULL
human	NULL
leukaemic	NULL
T-cells	NULL
.	NULL

Nature	NULL
294:770	NULL
.	NULL

3	NULL
.	NULL

Hinuma	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Komoda	NULL
,	NULL
T.	NULL
Chosa	NULL
,	NULL
T.	NULL
Kondo	NULL
,	NULL
M.	NULL
Kohakura	NULL
,	NULL
T.	NULL
Takenaka	NULL
,	NULL
M.	NULL
Kikuchi	NULL
,	NULL
M.	NULL
Ichimaru	NULL
,	NULL
K.	NULL
Yunoki	NULL
,	NULL
I.	NULL
Sato	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1982	NULL
.	NULL

Antibodies	NULL
to	NULL
adult	NULL
T-cell	NULL
leukemia-virus-associated	NULL
antigen	NULL
(	NULL
ATLA	NULL
)	NULL
in	NULL
sera	NULL
from	NULL
patients	NULL
with	NULL
ATL	NULL
and	NULL
controls	NULL
in	NULL
Japan	NULL
:	NULL
a	NULL
nation-wide	NULL
sero-epidemiologic	NULL
study	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
29:631	NULL
.	NULL

4	NULL
.	NULL

Xu	NULL
,	NULL
X.	NULL
,	NULL
S.	NULL
H.	NULL
Kang	NULL
,	NULL
O.	NULL
Heidenreich	NULL
,	NULL
M.	NULL
Oketholm	NULL
,	NULL
J.	NULL
J.	NULL
O'Shea	NULL
,	NULL
and	NULL
M.	NULL
I.	NULL
Nerenberg	NULL
.	NULL

1995	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
different	NULL
Jak	NULL
tyrosine	NULL
kinases	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
tax	NULL
protein	NULL
or	NULL
virus-transformed	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96:1548	NULL
.	NULL

5	NULL
.	NULL

Richardson	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
A.	NULL
J.	NULL
Edwards	NULL
,	NULL
J.	NULL
K.	NULL
Cruickshank	NULL
,	NULL
P.	NULL
Rudge	NULL
,	NULL
A.	NULL
G.	NULL
Dalgleish	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
vivo	NULL
cellular	NULL
tropism	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5682	NULL
.	NULL

6	NULL
.	NULL

Newbound	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
J.	NULL
M.	NULL
Andrews	NULL
,	NULL
J.	NULL
P.	NULL
O'Rourke	NULL
,	NULL
J.	NULL
N.	NULL
Brady	NULL
,	NULL
and	NULL
M.	NULL
D.	NULL
Lairmore	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
mediates	NULL
enhanced	NULL
transcription	NULL
in	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:2101	NULL
.	NULL

7	NULL
.	NULL

Hiraku	NULL
,	NULL
N.	NULL
,	NULL
R.	NULL
Hingorani	NULL
,	NULL
S.	NULL
K.	NULL
Machigashira	NULL
,	NULL
P.	NULL
K.	NULL
Gregersen	NULL
,	NULL
J.	NULL
Monteiro	NULL
,	NULL
K.	NULL
Usuku	NULL
,	NULL
S.	NULL
Yashiki	NULL
,	NULL
S.	NULL
Sonoda	NULL
,	NULL
M.	NULL
Osame	NULL
,	NULL
M.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Clonal	NULL
expansion	NULL
within	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
T-cell	NULL
subsets	NULL
in	NULL
human	NULL
T	NULL
lymphotropic	NULL
virus	NULL
type	NULL
L-infected	NULL
individuals	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:6674	NULL
.	NULL

8	NULL
.	NULL

Matsumoto	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Shibata	NULL
,	NULL
J.	NULL
I.	NULL
Fujisawa	NULL
,	NULL
H.	NULL
Inoue	NULL
,	NULL
A.	NULL
Hakura	NULL
,	NULL
T.	NULL
Tsukahara	NULL
,	NULL
and	NULL
M.	NULL
Fujii	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
transforms	NULL
rat	NULL
fibroblasts	NULL
via	NULL
two	NULL
distinct	NULL
pathways	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:4445	NULL
.	NULL

9	NULL
.	NULL

Pozzatti	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
Vogel	NULL
,	NULL
and	NULL
G.	NULL
Jay	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
tax	NULL
gene	NULL
can	NULL
cooperate	NULL
with	NULL
the	NULL
ras	NULL
oncogene	NULL
to	NULL
induce	NULL
neoplastic	NULL
transformation	NULL
of	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:413	NULL
.	NULL

10	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1991	NULL
.	NULL

Type	NULL
I	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
tax	NULL
protein	NULL
transforms	NULL
rat	NULL
fibroblasts	NULL
through	NULL
the	NULL
cyclic	NULL
adenosine	NULL
monophosphate	NULL
response	NULL
element	NULL
binding	NULL
protein/activating	NULL
transcription	NULL
factor	NULL
pathway	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88:1038	NULL
.	NULL

11	NULL
.	NULL

Tanaka	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Takahashi	NULL
,	NULL
S.	NULL
Yamaoka	NULL
,	NULL
T.	NULL
Nosaka	NULL
,	NULL
M.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
Hatanaka	NULL
.	NULL

1990	NULL
.	NULL

Oncogenic	NULL
transformation	NULL
by	NULL
the	NULL
tax	NULL
gene	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:1071	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

5103	NULL
Kanno	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Brown	NULL
,	NULL
G.	NULL
Franzoso	NULL
,	NULL
and	NULL
U.	NULL
Sicbenlist	NULL
.	NULL

1994	NULL
.	NULL

Kinetic	NULL
analysis	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
Tax-mediated	NULL
activation	NULL
of	NULL
NF-kB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6443	NULL
.	NULL

McKinsey	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Brockman	NULL
,	NULL
D.	NULL
C.	NULL
Scherer	NULL
,	NULL
S.	NULL
W.	NULL
Al-Murrani	NULL
,	NULL
P.	NULL
L.	NULL
Green	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Ballard	NULL
.	NULL

1996	NULL
.	NULL

Inactivation	NULL
of	NULL
by	NULL
the	NULL
tax	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
a	NULL
potential	NULL
mechanism	NULL
for	NULL
constitutive	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:2083	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Seiki	NULL
,	NULL
T.	NULL
Taniguchi	NULL
,	NULL
S.	NULL
Tsuru	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1986	NULL
.	NULL

Induction	NULL
of	NULL
interleukin	NULL
2	NULL
receptor	NULL
gene	NULL
expression	NULL
by	NULL
p40x	NULL
encoded	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:2883	NULL
.	NULL

Fujii	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Sassone-Corsi	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1988.	NULL
c-fos	NULL
promoter	NULL
trans-activation	NULL
by	NULL
the	NULL
tax1	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:8526	NULL
.	NULL

Sun	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
S.	NULL
B.	NULL
Maggirwar	NULL
,	NULL
E.	NULL
W.	NULL
Harhaj	NULL
,	NULL
and	NULL
M.	NULL
Uhlik	NULL
.	NULL

1999	NULL
.	NULL

Binding	NULL
of	NULL
c-Rel	NULL
to	NULL
Stat5	NULL
target	NULL
sequences	NULL
in	NULL
HTLV-L-transformed	NULL
T-cells	NULL
.	NULL

Oncogene	NULL
18:1401	NULL
.	NULL

Yin	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
L.	NULL
B.	NULL
Christerson	NULL
,	NULL
Y.	NULL
Yamamoto	NULL
,	NULL
Y.	NULL
T.	NULL
Kwak	NULL
,	NULL
S.	NULL
Xu	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
M.	NULL
Barbosa	NULL
,	NULL
M.	NULL
H.	NULL
Cobb	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1998	NULL
.	NULL

HTLV-I	NULL
Tax	NULL
protein	NULL
binds	NULL
to	NULL
MEKK1	NULL
to	NULL
stimulate	NULL
IKB	NULL
kinase	NULL
activity	NULL
and	NULL
NF-KB	NULL
activation	NULL
.	NULL

Cell	NULL
93:875	NULL
.	NULL

Uchiyama	NULL
,	NULL
T.	NULL
1997	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
and	NULL
human	NULL
diseases	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15:15	NULL
.	NULL

Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
1997	NULL
.	NULL

Stats	NULL
and	NULL
gene	NULL
regulation	NULL
.	NULL

Science	NULL
277:1630	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
,	NULL
J.	NULL
Blenis	NULL
,	NULL
H.-C.	NULL
Li	NULL
,	NULL
C.	NULL
Schindler	NULL
,	NULL
and	NULL
S.	NULL
Chen-Kiang	NULL
.	NULL

1995	NULL
.	NULL

Requirement	NULL
of	NULL
serine	NULL
phosphorylation	NULL
for	NULL
formation	NULL
of	NULL
Stat-promoter	NULL
complexes	NULL
.	NULL

Science	NULL
267:1990	NULL
.	NULL

Wen	NULL
,	NULL
Z.	NULL
,	NULL
Z.	NULL
Zhong	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1995	NULL
.	NULL

Maximal	NULL
activation	NULL
of	NULL
transcription	NULL
by	NULL
Statl	NULL
and	NULL
Stat3	NULL
requires	NULL
both	NULL
tyrosine	NULL
and	NULL
serine	NULL
phosphorylation	NULL
.	NULL

Cell	NULL
82:241	NULL
.	NULL

Ng	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
D.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

Stat3	NULL
is	NULL
a	NULL
serine	NULL
kinase	NULL
target	NULL
in	NULL
T	NULL
lymphocytes	NULL
:	NULL
interleukin	NULL
2	NULL
and	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
signals	NULL
converge	NULL
upon	NULL
serine	NULL
727	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:24542	NULL
.	NULL

Kirken	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
M.	NULL
G.	NULL
Malabarba	NULL
,	NULL
J.	NULL
Xu	NULL
,	NULL
L.	NULL
DaSilva	NULL
,	NULL
R.	NULL
A.	NULL
Erwin	NULL
,	NULL
X.	NULL
Liu	NULL
,	NULL
L.	NULL
Hennighausen	NULL
,	NULL
H.	NULL
Rui	NULL
,	NULL
and	NULL
W.	NULL
L.	NULL
Farrar	NULL
.	NULL

1997	NULL
.	NULL

Two	NULL
discrete	NULL
regions	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL2	NULL
)	NULL
receptor-	NULL
independently	NULL
mediate	NULL
IL2	NULL
activation	NULL
of	NULL
a	NULL
PD98059/	NULL
rapamycin/wortmannin	NULL
insensitive	NULL
StatSa/b	NULL
serine	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
:	NULL
15459	NULL
.	NULL

Kirken	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
M.	NULL
G.	NULL
Malabarba	NULL
,	NULL
J.	NULL
Xu	NULL
,	NULL
X.	NULL
Liu	NULL
,	NULL
W.	NULL
L.	NULL
Farrar	NULL
,	NULL
L.	NULL
Hennighausen	NULL
,	NULL
A.	NULL
C.	NULL
Lamer	NULL
,	NULL
P.	NULL
M.	NULL
Grimley	NULL
,	NULL
and	NULL
H.	NULL
Rui	NULL
.	NULL

1997	NULL
.	NULL

Prolactin	NULL
stimulates	NULL
serine/	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
formation	NULL
of	NULL
heterocomplexes	NULL
of	NULL
multiple	NULL
Stat5	NULL
isoforms	NULL
in	NULL
Nb2	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:14098	NULL
.	NULL

Yamashita	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Xu	NULL
,	NULL
R.	NULL
A.	NULL
Erwin	NULL
,	NULL
W.	NULL
L.	NULL
Farrar	NULL
,	NULL
R.	NULL
A.	NULL
Kirken	NULL
,	NULL
and	NULL
H.	NULL
Rui	NULL
.	NULL

1998	NULL
.	NULL

Differential	NULL
control	NULL
of	NULL
the	NULL
phosphorylation	NULL
state	NULL
of	NULL
proline-juxtaposed	NULL
serine	NULL
residues	NULL
Ser	NULL
'	NULL
``	NULL
of	NULL
StatSa	NULL
and	NULL
Ser'*	NULL
``	NULL
of	NULL
StatSb	NULL
in	NULL
prolactin-sensitive	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:30218	NULL
.	NULL

Thomis	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
J.	NULL
Berg	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Jak3	NULL
in	NULL
lymphoid	NULL
development	NULL
,	NULL
activation	NULL
,	NULL
and	NULL
signaling	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

9:541	NULL
.	NULL

Rolling	NULL
,	NULL
C.	NULL
,	NULL
D.	NULL
Treton	NULL
,	NULL
S.	NULL
Pellegrini	NULL
,	NULL
P.	NULL
Galanaud	NULL
,	NULL
and	NULL
Y.	NULL
Richard	NULL
.	NULL

1996	NULL
.	NULL

IL4	NULL
and	NULL
IL13	NULL
share	NULL
the	NULL
y	NULL
,	NULL
,	NULL
chain	NULL
and	NULL
activate	NULL
Stat6	NULL
,	NULL
Stat3	NULL
and	NULL
Stat5	NULL
proteins	NULL
in	NULL
normal	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

393:53	NULL
.	NULL

Malabarba	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
H.	NULL
Rui	NULL
,	NULL
H.	NULL
H.	NULL
Deutsch	NULL
,	NULL
J.	NULL
Chung	NULL
,	NULL
F.	NULL
S.	NULL
Kalthoff	NULL
,	NULL
W.	NULL
L.	NULL
Farrar	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Kirken	NULL
.	NULL

1996	NULL
.	NULL

Interleukin-13	NULL
is	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
Jak3	NULL
and	NULL
Stat6	NULL
in	NULL
cells	NULL
expressing	NULL
interleukin-2	NULL
receptor-y	NULL
and	NULL
interleukin-4	NULL
receptor-	NULL
.	NULL

Biochem	NULL
J	NULL
.	NULL

319:865	NULL
.	NULL

Yu	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
R.	NULL
A.	NULL
Kirken	NULL
,	NULL
M.	NULL
G.	NULL
Malabarba	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

Young	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Ortaldo	NULL
.	NULL

1998	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
the	NULL
Janus	NULL
kinase-Stat	NULL
pathway	NULL
and	NULL
biologic	NULL
function	NULL
of	NULL
IL-13	NULL
in	NULL
primary	NULL
human	NULL
NK	NULL
and	NULL
T-cells	NULL
:	NULL
a	NULL
comparative	NULL
study	NULL
with	NULL
IL-4	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:218	NULL
.	NULL

Moriggl	NULL
,	NULL
R.	NULL
,	NULL
D.	NULL
J.	NULL
Topham	NULL
,	NULL
S.	NULL
Teglund	NULL
,	NULL
V.	NULL
Sexl	NULL
,	NULL
C.	NULL
McKay	NULL
,	NULL
D.	NULL
Wang	NULL
,	NULL
A.	NULL
Hoffmeyer	NULL
,	NULL
J.	NULL
van	NULL
Deursen	NULL
,	NULL
M.	NULL
Y.	NULL
Sangster	NULL
,	NULL
K.	NULL
D.	NULL
Bunting	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

Stat5	NULL
is	NULL
required	NULL
for	NULL
IL-2-induced	NULL
cell	NULL
cycle	NULL
progression	NULL
of	NULL
peripheral	NULL
T-cells	NULL
.	NULL

Immunity	NULL
10:249	NULL
.	NULL

Xu	NULL
,	NULL
X.	NULL
,	NULL
S.	NULL
H.	NULL
Kang	NULL
,	NULL
O.	NULL
Heidenreich	NULL
,	NULL
M.	NULL
Okerholm	NULL
,	NULL
J.	NULL
J.	NULL
O'Shea	NULL
,	NULL
and	NULL
M.	NULL
I.	NULL
Nerenberg	NULL
,	NULL
M.	NULL
I	NULL
.	NULL

1995	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
different	NULL
Jak	NULL
tyrosine	NULL
kinases	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
tax	NULL
protein	NULL
or	NULL
virus-transformed	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96:1548	NULL
.	NULL

Migone	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
J.	NULL
X.	NULL
Lin	NULL
,	NULL
A.	NULL
Cereseto	NULL
,	NULL
J.	NULL
C.	NULL
Mulloy	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
O'Shea	NULL
,	NULL
G.	NULL
Franchini	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1995	NULL
.	NULL

Constitutively	NULL
activated	NULL
Jak-Stat	NULL
pathway	NULL
in	NULL
T-cells	NULL
transformed	NULL
with	NULL
HTLV-I	NULL
Science	NULL
269:79	NULL
.	NULL

Mulloy	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
T.	NULL
S.	NULL
Migone	NULL
,	NULL
T.	NULL
M.	NULL
Ross	NULL
,	NULL
N.	NULL
Ton	NULL
,	NULL
P.	NULL
L.	NULL
Green	NULL
,	NULL
W.	NULL
J.	NULL
Leonard	NULL
,	NULL
and	NULL
G.	NULL
Franchini	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
and	NULL
simian	NULL
T-cell	NULL
leukemia	NULL
viruses	NULL
type	NULL
2	NULL
(	NULL
HTLV-2	NULL
and	NULL
STLV-2	NULL
(	NULL
pan-p	NULL
)	NULL
)	NULL
transform	NULL
T-cells	NULL
independently	NULL
of	NULL
Jak/Stat	NULL
activation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:4408	NULL
.	NULL

Takemoto	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
C.	NULL
Mulloy	NULL
,	NULL
A.	NULL
Cereseto	NULL
,	NULL
T.	NULL
S.	NULL
Migone	NULL
,	NULL
B.	NULL
K.	NULL
Patel	NULL
,	NULL
M.	NULL
Matsuoka	NULL
,	NULL
K.	NULL
Yamaguchi	NULL
,	NULL
K.	NULL
Takatsuki	NULL
,	NULL
S.	NULL
Kamihira	NULL
,	NULL
J.	NULL
D.	NULL
White	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Proliferation	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
Jak/Stat	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:13897	NULL
.	NULL

Yu	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
D.	NULL
J.	NULL
Meyer	NULL
,	NULL
G.	NULL
S.	NULL
Campbell	NULL
,	NULL
A.	NULL
C.	NULL
Larner	NULL
,	NULL
C.	NULL
Carter-Su	NULL
,	NULL
J.	NULL
Schwartz	NULL
,	NULL
and	NULL
R.	NULL
Jove	NULL
.	NULL

1995	NULL
.	NULL

Enhanced	NULL
DNA-binding	NULL
activity	NULL
of	NULL
a	NULL
Stat3-related	NULL
protein	NULL
in	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
Src	NULL
oncoprotein	NULL
.	NULL

Science	NULL
269:81	NULL
.	NULL

Turkson	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Bowman	NULL
,	NULL
R.	NULL
Garcia	NULL
,	NULL
E.	NULL
Caldenhoven	NULL
,	NULL
R.	NULL
P.	NULL
De	NULL
Groot	NULL
,	NULL
and	NULL
R.	NULL
Jove	NULL
.	NULL

1998	NULL
.	NULL

Stat3	NULL
activation	NULL
by	NULL
Src	NULL
induces	NULL
specific	NULL
gene	NULL
regulation	NULL
and	NULL
is	NULL
required	NULL
for	NULL
cell	NULL
transformation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:2545	NULL
.	NULL

Murakami	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Nakano	NULL
,	NULL
Y.	NULL
Niho	NULL
,	NULL
N.	NULL
Hamasaki	NULL
,	NULL
and	NULL
K.	NULL
Izuhara	NULL
.	NULL

1998	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
Jak-2	NULL
and	NULL
Tyk-2	NULL
in	NULL
a	NULL
v-Src-transformed	NULL
human	NULL
gallbladder	NULL
adenocarcinoma	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

175:220	NULL
.	NULL

Cao	NULL
,	NULL
X.	NULL
,	NULL
A.	NULL
Tay	NULL
,	NULL
G.	NULL
R.	NULL
Guy	NULL
,	NULL
and	NULL
Y.	NULL
H.	NULL
Tan	NULL
.	NULL

1996	NULL
.	NULL

Activation	NULL
and	NULL
association	NULL
of	NULL
Stat3	NULL
with	NULL
Src	NULL
in	NULL
v-Src-transformed	NULL
cell	NULL
lines	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:1595	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5104	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

Bromberg	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
C.	NULL
M.	NULL
Horvath	NULL
,	NULL
D.	NULL
Besser	NULL
,	NULL
W.	NULL
W.	NULL
Lathem	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1998	NULL
.	NULL

Stat3	NULL
activation	NULL
is	NULL
required	NULL
for	NULL
cellular	NULL
transformation	NULL
by	NULL
v-src	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:2553	NULL
.	NULL

Chai	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
G.	NULL
L.	NULL
Nichols	NULL
,	NULL
and	NULL
P.	NULL
Rothman	NULL
.	NULL

1997	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
Jaks	NULL
and	NULL
Stats	NULL
in	NULL
BCR-Abl-expressing	NULL
cell	NULL
lines	NULL
and	NULL
peripheral	NULL
blood	NULL
cells	NULL
derived	NULL
from	NULL
leukemic	NULL
patients	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:4720	NULL
.	NULL

Weber-Nordt	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
C.	NULL
Egen	NULL
,	NULL
J.	NULL
Wehinger	NULL
,	NULL
W.	NULL
Ludwig	NULL
,	NULL
V.	NULL
Gouilleux-Gruart	NULL
,	NULL
R.	NULL
Mertelsmann	NULL
,	NULL
and	NULL
J.	NULL
Finke	NULL
.	NULL

1996	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
Stat	NULL
proteins	NULL
in	NULL
primary	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
and	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-related	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
88:809	NULL
.	NULL

Wang	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
R.	NULL
A.	NULL
Kirken	NULL
,	NULL
R.	NULL
A.	NULL
Erwin	NULL
,	NULL
C.	NULL
R.	NULL
Yu	NULL
,	NULL
and	NULL
W.	NULL
L.	NULL
Farrar	NULL
.	NULL

1999	NULL
.	NULL

Jak3	NULL
,	NULL
Stat	NULL
,	NULL
and	NULL
MAPK	NULL
signaling	NULL
pathways	NULL
as	NULL
novel	NULL
molecular	NULL
targets	NULL
for	NULL
the	NULL
tyrphostin	NULL
AG-490	NULL
regulation	NULL
of	NULL
IL-2-mediated	NULL
T-cell	NULL
response	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:3897.	NULL
.	NULL

Kirken	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
R.	NULL
A.	NULL
Erwin	NULL
,	NULL
D.	NULL
Taub	NULL
,	NULL
W.	NULL
J.	NULL
Murphy	NULL
,	NULL
F.	NULL
Behbod	NULL
,	NULL
L.	NULL
Wang	NULL
,	NULL
F.	NULL
Pericle	NULL
,	NULL
and	NULL
W.	NULL
L.	NULL
Farrar	NULL
.	NULL

1999	NULL
.	NULL

Tyrphostin	NULL
AG-490	NULL
inhibits	NULL
cytokine	NULL
mediated	NULL
Jak3/StatSa/b	NULL
signal	NULL
transduction	NULL
and	NULL
cellular	NULL
proliferation	NULL
of	NULL
antigen	NULL
activated	NULL
human	NULL
T-cells	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

65:891.	NULL
.	NULL

Gazit	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Yaish	NULL
,	NULL
C.	NULL
Gilon	NULL
,	NULL
and	NULL
A.	NULL
Levitzki	NULL
.	NULL

1989	NULL
.	NULL

Tyrphostins	NULL
.	NULL

I.	NULL
Synthesis	NULL
and	NULL
biological	NULL
activity	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Chem	NULL
.	NULL

32:2344	NULL
.	NULL

Levitzki	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
A.	NULL
Gazit	NULL
.	NULL

1995	NULL
.	NULL

Tyrosine	NULL
kinase	NULL
inhibition	NULL
:	NULL
an	NULL
approach	NULL
to	NULL
drug	NULL
development	NULL
.	NULL

Science	NULL
267:1782	NULL
.	NULL

Meydan	NULL
,	NULL
N.	NULL
,	NULL
T.	NULL
Grunberger	NULL
,	NULL
H.	NULL
Dadi	NULL
,	NULL
M.	NULL
Shahar	NULL
,	NULL
E.	NULL
Arpaia	NULL
,	NULL
Z.	NULL
Lapidot	NULL
,	NULL
J.	NULL
S.	NULL
Leeder	NULL
,	NULL
M.	NULL
Freedman	NULL
,	NULL
A.	NULL
Cohen	NULL
,	NULL
A.	NULL
Gazit	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Inhibition	NULL
of	NULL
acute	NULL
lymphoblastic	NULL
leukaemia	NULL
by	NULL
a	NULL
Jak-2	NULL
inhibitor	NULL
.	NULL

Nature	NULL
379:645	NULL
.	NULL

Clark-Lewis	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
S.	NULL
Sanghera	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
Pelech	NULL
.	NULL

1991	NULL
.	NULL

Definition	NULL
of	NULL
a	NULL
consensus	NULL
sequence	NULL
for	NULL
peptide	NULL
substrate	NULL
recognition	NULL
by	NULL
p44mpk	NULL
,	NULL
the	NULL
meiosis-activated	NULL
my-elin	NULL
basic	NULL
protein	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:15180	NULL
.	NULL

Gonzalez	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
D.	NULL
L.	NULL
Raden	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Davis	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
substrate	NULL
recognition	NULL
determinants	NULL
for	NULL
human	NULL
ERK1	NULL
and	NULL
ERK2	NULL
protein	NULL
kinases	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:22159	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

HTLV-1	NULL
TRANSFORMATION	NULL
DOES	NULL
NOT	NULL
REQUIRE	NULL
JAK3/STATS5	NULL
PATHWAY	NULL
Zhang	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Y.	NULL
Zhao	NULL
,	NULL
B.	NULL
T.	NULL
Chait	NULL
,	NULL
W.	NULL
W.	NULL
Lathem	NULL
,	NULL
M.	NULL
Ritzi	NULL
,	NULL
R.	NULL
Knippers	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Damell	NULL
,	NULL
Jr.	NULL
1998	NULL
.	NULL

Ser'*	NULL
``	NULL
-dependent	NULL
recruitment	NULL
of	NULL
MCMS	NULL
by	NULL
Statla	NULL
in	NULL
IFN-y-induced	NULL
transcriptional	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

17:6963	NULL
.	NULL

Azimi	NULL
,	NULL
N.	NULL
,	NULL
K.	NULL
Brown	NULL
,	NULL
R.	NULL
N.	NULL
Bamford	NULL
,	NULL
Y.	NULL
Tagaya	NULL
,	NULL
U.	NULL
Sicbenlist	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Waldmann	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
Tax	NULL
protein	NULL
trans-activates	NULL
interleukin	NULL
15	NULL
gene	NULL
transcription	NULL
through	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:2452	NULL
.	NULL

Bamford	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
A.	NULL
P.	NULL
Battiata	NULL
,	NULL
J.	NULL
D.	NULL
Burton	NULL
,	NULL
H.	NULL
Sharma	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Waldmann	NULL
.	NULL

1996	NULL
.	NULL

Interleukin	NULL
(	NULL
IL	NULL
)	NULL
15/IL-T	NULL
production	NULL
by	NULL
the	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
cell	NULL
line	NULL
HuT-102	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
human	NULL
T-cell	NULL
lymphotrophic	NULL
virus	NULL
type	NULL
I	NULL
region/	NULL
IL-15	NULL
fusion	NULL
message	NULL
that	NULL
lacks	NULL
many	NULL
upstream	NULL
AUGs	NULL
that	NULL
normally	NULL
attenuates	NULL
IL-15	NULL
mRNA	NULL
translation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:2897	NULL
.	NULL

Luo	NULL
,	NULL
H.	NULL
,	NULL
W.	NULL
P.	NULL
Hanratty	NULL
,	NULL
and	NULL
C.	NULL
R.	NULL
Dearolf	NULL
.	NULL

1995	NULL
.	NULL

An	NULL
amino	NULL
acid	NULL
substitution	NULL
in	NULL
the	NULL
Drosophila	NULL
hopTum-	NULL
Jak	NULL
kinase	NULL
causes	NULL
leukemia-like	NULL
hematopoietic	NULL
defects	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:1412	NULL
.	NULL

Xia	NULL
,	NULL
Z.	NULL
,	NULL
M.	NULL
R.	NULL
Baer	NULL
,	NULL
A.	NULL
W.	NULL
Block	NULL
,	NULL
H.	NULL
Baumann	NULL
,	NULL
and	NULL
M.	NULL
Wetzler	NULL
.	NULL

1998	NULL
.	NULL

Expression	NULL
of	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
proteins	NULL
in	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
blasts	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

58:3173	NULL
.	NULL

Frank	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
S.	NULL
Mahajan	NULL
,	NULL
and	NULL
J.	NULL
Ritz	NULL
.	NULL

1997	NULL
.	NULL

B	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
contain	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
)	NULL
1	NULL
and	NULL
Stat3	NULL
constitutively	NULL
phosphorylated	NULL
on	NULL
serine	NULL
residues	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100:3140	NULL
.	NULL

Noraz	NULL
,	NULL
N.	NULL
,	NULL
K.	NULL
Saha	NULL
,	NULL
F.	NULL
Ofttones	NULL
,	NULL
S.	NULL
Smith	NULL
,	NULL
and	NULL
N.	NULL
Taylor	NULL
.	NULL

1998	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
TCR	NULL
signaling	NULL
molecules	NULL
in	NULL
IL-2-independent	NULL
herpesvirus	NULL
saimiri-transformed	NULL
T-cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:2042	NULL
.	NULL

Bicsinger	NULL
,	NULL
B.	NULL
,	NULL
I.	NULL
Muller-Fleckenstcin	NULL
,	NULL
B.	NULL
Simmer	NULL
,	NULL
G.	NULL
Lang	NULL
,	NULL
S.	NULL
Wittmann	NULL
,	NULL
E.	NULL
Platzer	NULL
,	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
,	NULL
and	NULL
B.	NULL
Fleckenstein	NULL
.	NULL

1992	NULL
.	NULL

Stable	NULL
growth	NULL
transformation	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
by	NULL
herpesvirus	NULL
saimiri	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:3116	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

